#### Exhibit 34-3

State of California ex rel. Ven-A-Care of the Florida Keys, Inc. v. Abbott Labs, Inc. et al., Civil Action No. 03-11226-PBS

Exhibit to the November 25, 2009 Declaration of Philip D. Robben in Support of Defendants' Joint Motion for Partial Summary Judgment

#### (Limite Acquisition Cost Summary by Drug Top 200 Multi-Source Drug Products without an FUL Study of Medi-Cal Pharmacy Reimbursement

ed
₽
Observations
from
External
Invoices)

		2.0%	7.2%	0.8551	0.0614	20	CLONAZEPAM 1MG TABLET	00093083301
		1.8%	20.0%	1.1912	0.2361	23	CLINDAMYCIN HCL 150MG CAPS	00364233701
		6.3%	61.5%	2.5587	1.5744	¢υ	CARTIA XT 300MG CAPSULE SA	62037060090
		1.6%	61.5%	1.9748	1.2147	4	CARTIA XT 240MG CAPSULE SA	62037059990
		7.9%	65.4%	1.3928	0.9103	12	CARTIA XT 180MG CAPSULE SA	62037059890
		6.6%	60.6%	1 1547	0.6998	13	CARTIA XT 120MG CAPSULE SA	62037059790
4 95.2%	0.9534	1.5%	80.2%	1.1321	0.9075	37	CARDURA 8MG TABLET	00049278066
	0.9079	1.8%	80.0%	1.0781	0.8627	103	CARDURA 4MG TABLET	00049277066
	0.8649	1.8%	80.2%	1.0271	0.8233	95	CARDURA 2MG TABLET	00049276066
	0.8642	1.8%	. 79.8%	: 0271	0,8198	39	CARDURA IMO TABLET	00049275066
i			83.5%	2.8740	2.4003	4	CARDIZEM CD 300MG CAP SA	00088179830
-		2.3%	82.3%	2.8740	2,3664	14	CARDIZEM CD 300MG CAP SA	00088179842
		0.4%	84.0%	2.1940	1.8424	12	CARDIZEM CD 240MG CAP SA	00088179730
		0.7%	83.2%	2,1940	1.8253	30	CARDIZEM CD 240MG CAP SA	00088179742
		0.5%	83.0%	1,6180	1.3435	10	CARDIZEN CD 160MG CAP SA	00088179630
		0.6%	79.9%	1.6180	1.2934	. 43	CARDIZEM CD 180MG CAP SA	00088179642
		0.5%	81.8%	1.3080	1.0701	20	CARDIZEM CD 120MG CAP SA	00088179542
		3.9%	66.9%	1.7158	1.1471	49	CARBIDOPA/LEVO 50/200 TB SA	00378009401
		5.2%	44.9%	0.7208	0.3234	49	BUPPOPION HOL 75MG TABLET	00093028001
		5.2%	45.0%	0.9616	0.4332	44	BUPROPION HOL 100MG TABLET	00093029001
		0.6%	80.2%	2.6442	2:209	26	BETAPACE SOME TABLET	50419010510
. —		5.4%	35.6%	1.3108	0.4664	29	AZATHIOPRINE SOMG TABLET	00054408425
			11,3%	0.3690	0.0418	8	AMOXICILLIN 500MG CAPSULE	00093310905
		3.1%	18.3%	3,1339	0.5729	9	AMIODARONE HCL 200MG TABLET	00781120360
100.0%	0.8636	1.1%	80.0%	1.0794	0.8636	138	ALESSE-28 TABLET	00008257602
			19,3%	0.8251	0 1590	_	ALBUTEROL SMG/ML SOLUTION	50383074120
		2.4%	22.2%	0.7495	0.1661	172	ALBUTEROL SMG/ML SOLUTION	59930151504
	•	1.4%	80.2%	1.2334	0.9890	139	ADALATICO 30MG TABLET SA	00026884151
		0.6%	83.5%	2.8040	2.3416	29	ACTIGALL 300MG CAPSULE	00078031905
		2.3%	69.8%	0.4285	0.2990	47	ACTICIN 5% CREAM	25074013106
	Ι	G	IJ	μı	D	0	to	Þ
DT	applicable)	Deviation	of AWP	AWP	Cost	Obs	Description	NDC Number
CO	DP (ii		Cost as %		Acquisition	No. of		
Acquisition		تازيد	Acquisition		Actual			
Average			Average		Average	7.0		

## Acquisition Cost Summary by Drug Top 200 Multi-Source Drug Products without an FUL Study of Medi-Cal Pharmacy Reimbursement

(Limited to Observations from External Invoices)

			Average		Average			Average
		1	Actual		Acquisition		3	Acquisition
		. 7	Acquisition		Cost as %	Standard	9	COS( 88 % OI
NDC Number	Description	Obs	Cost	AWP	OJ AWK	Deviation	аррисаріє	UT
Ъ	В	0	O	M	Ίď	G	ι	*.
00228300411	CLONAZEPAM 1MG TABLET	41	0,0423	0.8574	4.9%	0.5%	-	
52544074701	CLONAZEPAM 1MG TABLET	31	0.0533	0.8551	6.2%	1.6%	•	
00228300450	CLONAZEPAM 1MG TABLET	4	0.0440	0,8552	5.1%	0.5%		
00093083401	CLONAZEPAM 2MG TABLET	14	0.0835	1.1840	7.0%	2.2%		-
00228300511	CLONAZEPAM 2MG TABLET	17	0,0534	1.1877	4.5%	0.5%		
59930157003	CLOTRIMAZOLE 1% CREAM	30	0.0789	0.3612	21.8%	1.5%		
59930157002	CLOTRIMAZOLE 1% CREAM	77	0.0638	0.4466	14.3%	2.6%		
51672127502	CLOTRIMAZOLE 1% CREAM	7	0.0918	0.7504	12.3%	5.3%		
00172436060	CLOZAPINE 100MG TABLET	4	1.4828	3,1695	46.8%	2.8%		
00172436070	CLOZAPINE 100MG TABLET	on	1.4381	3.1695	45.4%	2.4%		
00172435960	CLOZAPINE 25MG TABLET	23	0.5591	1.2235	45.7%	5.1%		
00078012705	CLOZARIL 100MG TABLET	38	2.9473	3,5226	83.7%	0.8%		
00078012605	CLOZARIL 25MG TABLET	7	1.1328	1.3596	83.3%	0.5%		
00008418804	CORDARONE 200MG TABLET	7	2,4452	3,6696	66.6%	22.6%	2.9357	83.3%
00056016970	COUMADIN 1MG TABLET	69	0.5304	0.6304	84.1%	1.7%		
00056017670	COUMADIN 2.5MG TABLET	67	0.5702	0.6838	83.4%	1.3%		
00056017070	COUMADIN 2MG TABLET	107	0.5538	0.6625	83.6%	1.3%		
00056017270	COUMADIN SMG TABLET	124	0.5796	0.6928	83.7%	1.0%		
00032122001	CREON 20 CAPSULE SA	10	1.3047	1.6129	80.9%	1.2%		
49502068912	CROMOLYN NEBULIZER SOLUTION	10	0.1283	0.3500	36.7%	3.8%		
00075245201	DDAVP 0.01% NASAL SPRAY	23	24.4111	30.3900	80.3%	0.8%		
24208034205	DESMOPRESSIN O.1MG/ML SPRAY	29	15.6601	27.0480	57.9%	6,4%		<u>.</u>
00074374113	DICAL-D TABLET	íe	0.1299	0.1616	80,4%	1.0%	0.1360	95.5%
00071036224	DILANTIN 100MG KAPSEAL	240	0.2255	0 2698	83.6%	1.2%	0.2563	88.0%
00071036232	DILANTIN 100MG KAPSEAL	47	0.2237	0.2698	82.9%	2.1%	0.2563	87.3%
00071221420	DILANTIN 125MG/SML SUSP	8	0.1186	0.1477	80.3%	7.6%	0.1403	84.5%
00044102402	DILAUDID 4MG TABLET	Ŋ	0.6492	0.7731	84.0%	1.2%		
00378534001	DILTHAZEM ER 240MG CAP SA	47	0.4148	1.1460	36.2%	8.9%		
00228257709	DILTIAZEM HCL 180MG CAP SA	<del>16</del>	0.7468	1.2854	58.1%	2.4%		
00228257809	DILTIAZEM HCL 240MG CAP SA	17	1.0773	1.8234	59.1%	1.0%		

Myers and Stauffer LC

CA\_EAC\_exhibits.xls [MSNF-By-Drug · AWP]

### Study of Medi-Cal Pharmacy Reimbursement Acquisition Cost Summary by Drug Top 200 Multi-Source Drug Products without an FUL

(Limited to Observations from External Invoices)

	4.7%	30.0%	0.7056	0.2115	64	IPRATROPIUM BR 0.02% SOLN	49502068503
	1.3%	83.9%	1.5397	1.2912	23	IMDUR 60MG TABLET SA	00085411003
	0.3%	12.7%	0.2902	0.0367	88	IBUPROFEN 800MG TABLET	00364213705
	0.8%	12.1%	0.3048	0.0369	67	IBUPROFEN BOOMS TABLET	49884046905
	0.7%	11.1%	0.2288	0.0254	છ	IBUPROFEN 600MG TABLET	00364076605
	0.6%	10.5%	0.2403	0.0252	70	BUPROFEN 600MG TABLET	49884046805
	2.9%	64.2%	0.0505	0.0325	59	IBUPROFEN 100MG/SMIL SUSP	00472127016
1.6060 95.3%		80.2%	1.9071	1.5301	15	HYTRIN SMG CAPSULE	00074380713
		80.3%	1.9071	1.5313	2	HYTRIN 2NG CAPSULE	00074380613
		83.9%	2.4100	2.0219	98	HUMULIN R 190U/ML VIAL	00002821501
	0.9%	84.0%	2.4106	2.0239	202	HUMULIN N 100UWL VIAL	00002831501
	0.9%	83.8%	2,4100	2.0189	208	HUMULIN 70/30 VIAL	00002871501
		37.9%	47,5200	18,0000		HALOPERIDOL DEC 100MG/MI, VL	00703702301
	19.0%	50.2%	49.5000	24.8667	ω	HALOPERIDOL DEC 100MG/ML VL	63323047105
	0.5%	83.3%	62.1093	51.7513	ω	HALDOL DECANDATE 100 VIAL	00045025446
		7.1%	0.7770	0.0550		GLYBURIDE SMG TABLET	55953034440
		8.4%	0,5305	0,0446		GLYBURIDE SMG TABLET	00781145710
	4.1%	13.0%	0.7529	0.0979	24	GLYBURIDE SMG TABLET	59762372704
		15.3%	0.7771	0.1190	4	GLYBURIDE SMG TABLET	38245036410
	1.2%	14.0%	0.7412	0.1033	ជ	GLYBURIDE SMG TABLET	38245036420
	3.6%	8.9%	0.5812	0.0603	7	GLYBURIDE SMG TABLET	55953034480
	4.7%	12.7%	0.6292	0.0817	26	GLYBURIDE SMG TABLET	59762372707
	B.4%	36.8%	0.0260	0.0096	27	FOLIC ACID 1MG TABLET	00364013702
	0.3%	83.5%	49.8700	41 6266	ເກ	EPOGEN 40000/ML VIAL	55513014810
		83.5%	263.0800	219.7780		EPOGEN 20000U/ML VIAL	55513047810
	1.3%	84.2%	124.6800	104.9472	ထ	EPOGEN 10000U/ML VIAL	55513014410
		5.8%	1.5237	0,0882	N	ENALAPHIL MALEATE 20MG TAB	00781123301
		5.6%	1.0711	0.0603	~ <b>.</b>	ENALAPRIL MALEATE 10MG TAB	00781123201
	4.1%	19.3%	0.4800	0.0925	נס	DIPHENOXYLATE/ATROPINE TAB	00378041510
	3.7%	58.8%	1,9721	1.1602	35	DILTIAZEM HOL 240MG CAP SA	00093511898
-t	٠ •	TN	ľη	O	0	<b>c</b> o	A
ŀ				COOK	Cys.	Description	MOC Multipel
	2		e WD	2	) ,		
	Standard DP ()f			Acquisition	Z 0 ₽		
Acquisition		Acquisition		Actual			
Average		Average		Average			

CA\_EAC\_exhibits.xls [MSNF-By-Drug - AWP]

Myers and Stauffer LC

### Acquisition Cost Summary by Drug Top 200 Multi-Source Drug Products without an FUL Study of Medi-Cal Pharmacy Reimbursement

(Limited to Observations from External Invoices)

			Average		Average			
			Actual		Acquisition			Acquisition
		N 0	Acquisition		Cost as %	Standard	DP (II	Cost as % of
NDC Number	Description	Obs.	Cost	AWP	of AWP	Deviation	Deviation applicable)	UP.
<b>&gt;</b>	Ü	0	0	ťη	Τħ	6	I	~
00054840211	IPRATROPIUM BR 0.02% SOLN	19	0.1967	0.5875	33.5%	5.4%		
59930154901	ISOSORBIDE MN 60MG TAB SA	120	0.1188	1.1740	10.1%	2.6%		
00228271111	ISOSORBIDE MN 60MG TAB SA	N	0.2845	1.3591	20.9%		1	) )
00005328643	KETOPROFEN 75MG CAPSULE	19	0.0902	1.0221	8.8%	0.9%	0.9710	9.3%
59930163601	LABETALOL HOL 200MG TABLET	23	0.1238	0.6811	18.2%	0.9%		
00173024275	LANOXIN 125MCG TABLET	59	0.1324	0.1960	68.3%	8.4%		
00173024255	LANOXIN 125MCG TABLET	19	0.1720	0.2081	82.7%	2.3%		
00173024975	LĄNOXIN 250MCG TABLET	20	0.1308	0.1654	79.1%	2.0%		
00054252731	LITHIUM CARBONATE 300MG CAP	20	0.1316	0.1617	81.4%	40%	•	
00793126210	CHOICK CANBONA IS STORE ON	4	0 1213	0.4786	25.3%	5.4%		
00032421001	LUVOX 100MG TABLET	4.	2.2970	2.8771	79.8%	1 7%		
00032420501	LUVOX SOMG TABLET	37	2.2558	2.8078	80.3%	0.8%		
00555057202	METHOTREXATE 2.5MG TABLET	42	0.3361	3,6295	9.3%	3.7%		
59911587401	METHOTREXATE 2.5MG TABLET	4	0.6432	3.6347	17.7%			
00062141101	MICRONOR TABLET	86	1.0728	1.2798	83.8%	0.8%		
00062543403	MONISTAT-DERM 2% CREAM	ω	0.5407	0.6431	84.1%	0.7%		
60951065370	MORPHINE SULF 30MG TAB SA	13	0.9488	1.6946	56.0%	3.8%		
60951065570	MORPHINE SULF 60MG TAB SA	<u>:</u> ::	1.8686	3,3061	56.5%	2.5%	-	
00034051710	MS CONTIN 100MG TABLET SA	15	4.3956	5.4699	80.4%	1.0%		
00034051510	MS CONTIN 30MG TABLET SA	12	1,4589	1.8934	77.1%	9.3%	•	
00034051610	MS CONTIN 60MG TABLET SA	ō	2.4791	3.6944	5/.1%	20.2%		
51479004701	MYAMBUTOL 400MG TABLET	12	1.5866	1.9851	79,9%	%C.3%		
24208063110	NEO/POLYMYXIN/HC EAR SOLN	100	0.7673	2.8000	27.4%	0.1 %		
24208063562	NEO/POLYMYXIN/HC EAR SUSP	200	5 1072	£ 1071	% A E &	0.5%		
00078027422	MEDBAL 100MG/MI SOLUTION	N 1	5.5658	6,6566	83.6%	0.3%		
00078024615	NEORAL 25MG GELATIN CAPSULE	23	1.2779	1.5283	83.6%	06%		
00378347501	NIFEDIPINE ER 30MG TAB SA	17	0.9095	1,2915	70,4%	5.0%		
00093102101	NIFEDIPINE ER 30MG TAB SA	75	0.7063	1.0814	65.3%	4.4%		

CA\_EAC\_exhibits.xis [MSNF-By-Drug - AWP]

### (Limite Acquisition Cost Summary by Drug Top 200 Multi-Source Drug Products without an FUL Study of Medi-Cal Pharmacy Reimbursement

ed.
₫
Observations
from
External
Invoices)

Average Acquisition Acquisition Acquisition Acquisition Acquisition Deviation applicable)  E F G 2.2678 70.2% 2.3% 2.6121 68.2% 1.7% 0.0867 83.2% 0.5% 0.0778 51.0% 0.5% 1.1400 81.5% 1.0% 2.4100 62.3% 18.4% 4.5395 55.0% 11.8% 1.6532 53.9% 13.6% 3.254 46.9% 19.2% 3.0594 35.0% 7.8% 0.6403 14.3% 1.4% 0.6405 15.5% 0.0587 73.8% 3.3% 0.1250 73.8% 3.3% 0.2451 61.8% 13.9% 0.2451 61.8% 13.9% 0.2451 61.8% 13.9% 0.2456 79.7% 1.5% 1.2013 1.3980 80.4% 0.99% 2.2688 79.8% 0.99% 0.0588	82.5%	20708	1.8%	19.3%	2.4192	1.9187	G	PROCARDIA XL BOMG TABLET SA	00069266072
Average Average Acquisition Ac	94./%	2.0788	0.9%	79.8%	2.4686	1.9695	24	PROCARDIA XL 60MG TABLET SA	00069266066
Average Average Average Average Average Acquisition Description Obs Cost Acquisition Average Cost as % Standard DP (II Cos	93.5%	1.2013	0.9%	80,4%	1.3980	1.1233	26	PROCARDIA XL 30MG TABLET SA	00069265072
Average Averag	94.7%	1.2013	1.5%	79.7%	1,4266	1.1374	29	PROCARDIA XL 30MG TABLET SA	00069265066
Average Actual A				83.4%	0.0587	0.0490	3	PREGESTIMIL POWDER	00087035701
Actual Ac				1.3%	2.6391	0.0339	16	PIROXICAN 20MG CAPSULE	00378202001
Actual Ac			34%	64.8%	0.2451	0,1588	28	PHENYTOIN SOD EXT 100MG CAP	00378156001
Acquisition    Acquisition   A	•		1.3%	61.8%	0.2451	0.1514	<del>1</del> 0	PHENYTOIN SOD EXT 100MG CAP	00378156010
Average Acquisition Acquisition Acquisition Cost Acquisition Cost Acquisition Acquisition Cost Acquisition Cost Acquisition Cost Acquisition DP: (II Cost as:% Standard DP: (II Cost as:% Standa			3.3%	73.8%	0.1250	0.0922	9	PHENYTOIN 125MG/SML SUSPEN	00472006708
Acturage Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Cost as % Standard DP (II Cost as % Standard DP) Acquisition Applicable)  F		•		66.5%	0.0351	0.0233	_	PEPTAMEN LIQUID	00065906770
Average Actual Average Actual Average Actual Actual Acquisition AMP Cost as % Shandard DP (if Cost as % Shandard DP (if AWP) Deviation AMP Deviation AMP Deviation AMP Deviation Applicable)  8 C				15.6%	0.6405	0.1001		PENTOXIFYLLINE 400MG TAB SA	00228261111
Average Actual Average Actual Average Actual Actual Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition AWP Cost as % Acquisition Awp Cost as			1.4%	14.3%	0.6403	0.0916	26	PENTOXIFYLLINE 400MG TAB SA	00378035701
Average Actual Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Cost as % Standard DP (if Cost as % Standard DP (if Cost as % Standard DP (if Acquisition AWP Deviation applicable) ACQUISITION AWP DEVIATION AWP DEV			1.0%	15.5%	0.5940	0.0919	т 4	PENTOXIFYLLINE 400MG TAB SA	38245067210
Average Average Average Average Average Average Actual Actual Acquisition Average Acquisition Acquisition Average				29.5%	0.0058	0.0017		REDIATRIC ELECTROLYTE SOLN	24385009647
Average Average Actual			7.8%	35.0%	3,0594	1.0700	53	PACERONE 200MG TABLET	00245014760
Average Average Actual			18.2%	46.9%	3.2254	1.5133	œ	ORAMORPH SR 60MG TABLET SA	00054479225
Average			13.6%	53.9%	1.6532	0.8919	Ç	ORAMORPH SRIGOMG TABLETISA	00054480525
Average			11.8%	55,0%	4.9395	2.7162	8	CRAMORPH SR 100MG TABLET SA	00054479325
Average	-		:8.4%	62.3%	2,4100	1.5008	40	NOVOLIN E 1000/ML VIAL	00169183311
Average			15.6%	72.1%	2,4100	1.7386	59	NOVOUN N 1000MML VIAL	00169183411
Average			0.9%	80.3%	4,3330	3.4777	16	NOVOLIN 70/30 U100 CARTRIDG	00169347718
Average			12.5%	75.5%	2.4111	1.8201	109	NOVOLIN 76/30 100U/ML VIAL	00169183711
Average			1.0%	81.5%	1,1400	0.9295	23	NOR-Q-D TABLET	52544023528
Average Average Average Average Average Actual Actual Acquisition Actual Acquisition Acquisition Acquisition Acquisition DP. [II Cost as % Standard DP. [II			0.6%	82.5%	0.7853	0.6475	123	NORCO 10/325 TABLET	52544053901
Average Average Average Average Average Actual Actual Actual Actual Acquisition Actual Acquisition Actual Acquisition Acquisition DP. (II Cost as % Standard			0.7%	83.8%	0.9853	0.8257	53	NIZORAL 2% CREAM	50458022130
Average Average Average Average Average Acquisition Actual Acquisition Acquisition Acquisition Acquisition Acquisition Cost as % Standard DP. (If Cost as %			0,9%	84.0%	0,7589	0.6378	57	NIZORAL 2% CREAM	50458022160
Average         Average         Average         Average           Actual         Acquisition         Acquisition         Acquisition           Poscription         Obs.         Cost         AWP         Of AWP         Deviation         OP. If           In NEEDIPINE ER SOMG TAB SA         21         1.5925         2.2678         70.2%         2.3%           In NIFEDIPINE ER SOMG TAB SA         17         1.7813         2.6121         68.2%         3.4%           In NIFEDIPINE ER SOMG TAB SA         17         1.7813         2.6121         68.2%         3.4%           In NIFEDIPINE ER SOMG TAB SA         17         1.7813         2.6121         68.2%         3.4%           In NIFEDIPINE ER SOMG TAB SA         17         1.7813         2.6121         68.2%         3.4%           In NIFEDIPINE ER SOMG TAB SA         17         1.7813         2.6121         68.2%         3.4%           In NIFEDIPINE ER SOMG TAB SA         17         1.7813         2.6121         68.2%         3.4%           In NIFEDIPINE ER SOMG TAB SA         17         1.7813         2.6121         68.2%         3.4%	40.2%	0.1794	1.7%	83.2%	0.0867	0,0721	ဒ္ဌ	NITROSTAT 0.4MG TABLET.SL	00071057024
Average Average Average Average Average Average Actual Acquisition Acquisition Cost as % Standard DP. (II Cost as % Standard DP.			4.5%	51.0%	0.077B	0.0396	187	NITRODUICK 0.4MG TABLET SL	58177032404
Average Average Average Average Average Acquisition Acquisition Acquisition Cost as % Standard DP. (If Description Obs. Cost AWP of AWP Deviation applicable)  B C D E F G H  NIFEDIPINE ER SOMG TAB SA 21 1.5925 2.2678 70.2% 2.3%			3.4%	68 2%	2.6121	1.7813	17	NIFEDIPINE ER 90MG TAB SA	00378349501
Average Average Acquisition Acquisition  Description  Cost Cost  AWP  ACQUISITION  AWP  AWP  AWP  AWP  AWP  AWP  B  AWP  AWP			2.3%	70.2%	2.2678	1.5925	23	NIFEDIPINE ER SOMG TAB SA	00378348201
Average Average Acquisition Actual Acquisition Cost as % Standard DP (II Description Obs Cost AWP of AWP Deviation applicable)		I	۵	Τſ	ш	O	0	CO.	Ā
Average Average Actual Acquisition Acquisition DP. II	UP	applicable)		of AWP	AWP	Cost	Obs.		NDC Number
Acquistion	ost as % of	٠	Standard	Cost as %		Acquisition	<. · · · ·		
A CONTRACT CONTRACTOR OF THE C	cquisition	äl		Acquisition		Actual			
	Average			Average		Average			

i

#### (Limited Acquisition Cost Summary by Drug Top 200 Multi-Source Drug Products without an FUL Study of Medi-Cal Pharmacy Reimbursement

D.
õ
Observat
tions i
from Ext
External
invoices)

Average   Aver			0.5%	84.3%	0.0892	0.0752	Û	TYLENOL EX-STR SOOMS CAPLET	00045044909
Average Averag			0.8%	11.6%	0.3807	0.0440	70	TRIMOX SOOMG CAPSULE	00003010960
Average Averag	100.5%	4.9760	0.8%	80.4%	6.2200	5.0012	83	TIMOPTIC-XE 0.5% EYE SOLN	00006355803
Average Averag			1.9%	62.2%	5,5995	3,4829	96	TIMOLOL 0.5% GEL/SOLUTION	61314022505
Average Actual:  No of Actual:  No of Actual:  No of Actual:  No of Actual:  Average Actual:  Average Actual:  Average Actual:  Cost as % Standard AWP of AWP Deviation opplicable)  PROCHORM 100			0.5%	83.8%	2.1762	1.8228	17	TICLID 250MG TABLET	00004001822
Average Actual:  No. of Acquisition  Description  No. of Acquisition  Obs:  Cost:  AWP  PROCAPDIA XL 90MG TABLET SA PROCHI TODOCUMIL VIAL PROCHIT 4000UML VIAL PROCHIT 41 21 11.9383 12.46% 12.8% PROCHIT 4000UML VIAL PROCHIT 4000UML PRO				18.8%	0.5398	0.1013		THIORIDAZINE 50MG TABLET	00781163401
Average Acquisition  Acquisition Acquisiti			2.6%	21.7%	0.6337	0.1375	Ы	THIORIDAZINE 100MG TABLET	00781164401
Average Acquisition  Acquisition Acquisition  Acquisition  Acquisition  Cost as % Standard DP (If Acquisition)  Acquisition  Cost as % Standard DP (If Acquisition)  Acquisition  Cost as % Standard DP (If Acquisition)  Acquisition  Acquisition  Acquisition  Acquisition  DP (If Acquisition)  Acquisition  Acquisition  DP (If Acquisition)  Acquisition  Acquisi			3.5%	14,9%	1.6038	0.2389	84	TERAZOSIN SMG CAPSULE	00781205301
Average Average Average Average Average Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Cost as % Standard DP (If DP (If DP (If Cost as % Standard DP (If DP (If DP (If DP (If Cost as % Standard DP (If DP			4.1%	15.4%	1.6038	0.2467	70	TERAZOSIN 2MG CAPSULE	00781205201
Average Average Average Average Average Acquisition No. of Acquisition Cost as % Standard Acquisition Application			3.0%	14.9%	1.6038	0.2382	37	TERAZOSIN IMG CAPSULE	00781205101
Average Average Acquisition No, of Acquisition Cost as % Standard Acquisition AMP Cost as % Standard Acquisition Cost as % Standard AMP Deviation applicable)  B C D If Cost as % Standard AMP Deviation applicable)  B C D If Cost as % Standard AMP Deviation applicable)  B C D If Cost as % Standard AMP Deviation applicable)  B C D If Cost as % Standard AMP Deviation applicable)  B C D If Cost as % Standard AMP Deviation applicable)  B C D If Cost as % Standard AMP Deviation applicable)  B C D If Cost as % Standard AMP Deviation applicable)  B C D If Cost as % Standard AMP Deviation applicable)  Cost as % Standard AMP Deviation applicable)  B C D If Cost as % Standard AMP Deviation applicable)  Cost as % Standard AMP Deviation applicable)  D If Cost as % Standard AMP Deviation applicable)  Cost as % Standard AMP Deviation applicable)  If Cost as % Standard AMP Deviation applicable  If Cost as % Standard AMP Deviation applicable  If Cost as % Standard AMP Deviation applicable  If Cost as % Standard If Cost as			2.3%	14.1%	1.6038	0.2259	28	TERAZOSIN 10MG CAPSULE	00781205401
Average Actual Actual Acquisition Acquisit			1.4%	8.0%	0.8107	0.0646	53	TEMAZEPAM 30MG CAPSULE	00378505001
Average			2.3%	7.5%	0.6947	0.0523	58	TEMAZEPAM 15MG CAPSULE	00378401001
Average Average Actual Actual Actual Actual Actual Actual Actual Actual Actual Acquisition Actual Acquisition Actual Acquisition Actual Acquisition Ac			2.5%	78.0%	3,64219	2.8408	<u>თ</u>	TAMOXIFEN 20MG TABLET	00555090401
Average Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Cost as% Standard Cost as% S			2.0%	77.1%	1.8189	1,4030	76	TAMOXIFEN YOMG TABLET	00555044609
Average Average Actual Acquisition Actual Acquisition Actual Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Actual Acquisition			2.8%	24.0%	0.7295	0.1754	42	SUCRALFATE IGM TABLET	00093221001
Average Average Average Actual Actual Actual Actual Actual Actual Actual Acquisition Acquisition Acquisition Acquisition Cost as % Standard DP (If Cost as % Standard DP) (If Cost as %		•	0.8%	20.7%	0.7295	0.1513	4	SUCRALFATE 13M TABLET	00093221005
Average Average Average Actual Actual Actual Actual Acquisition Acquisition Acquisition Acquisition Acquisition Cost as % Standard DP (If Cost as % Standard DP) (If Cost as % Standard				25.5%	0.1061	0.0271	_	SODIUM CHLORIDE 0.9% VIAL	00054880925
Average Average Average Average Actual Actual Actual Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Cost as % Standard DP (if Cost as % Standard DP) (if Cost			13.1%	49.5%	0.0591	0.0274	1 8	SODIUM CHLORIDE 0.9% VIAL	49502083003
Average Average Average Average Actual Actual Actual Acquisition Actual Acquisition Acquis		•	1.7%	79.2%	1.9159	1.5180	35	SINEMET CR 50/200 TABLET SA	00056052168
Average Average Average Average Average Actual Actual Acquisition				46.9%	0.0077	0.0036	ယ	RESOURCE DIABETIC LIQUID	00212339162
Average Average Average Average Average Acquisition Actual Acquisition Acquisi		•	2.6%	83.1%	50,0906	41,6367	16	PADCRIT 4000UML VIAL	59676030401
Average Average Average Average Average Actual Actual Acquisition Actual Acquisition Applicable)  PROCARDIA XL 90MG TABLET SA 19 2.2817 2.8482 80.1% 1.0% 2.3985 PROCHLOAPERAZINE 15MG TAB 29 0.1130 0.8140 13.9% 2.4% PROCHLOAPERAZINE 25MG SUPP 64 2.1192 2.9931 70.9% 6.1% PROCHIT 100000/JML VIAL 15 102.1505 124.9712 81.7% 2.7% PROCHIT 100000/JML VIAL 2 101.9383 124.6800 81.8% 5.1% PROCHIT 200000/JML VIAL 7 201.3450 249.3600 80.7% 3.4% PROCRIT 200000/JML VIAL 5 30.2195 37.4034 80.8% 2.5%			2,8%	84.3%	501.6300	422,9438	o,	PROCRIT 40000U/ML VIAL	59676034001
Average Average Average Average Average Actual Actual Acquisition Actual Acquisition Actual Acquisition Applicable)  PROCARDIA I 905. Cost. AWP. 6/1 AWP. Deviation applicable)  PROCARDIA I 906. TABLET SA 19 2.2817 2.8482 80.1% 1.0% 2.3985  PROCHLORPERAZINE 25MG SUPP 64 2.1192 2.9931 70.9% 6.1% 6.1%  PROCEIT 10000UMIL VIAL 15 102.1505 124.9712 81.7% 2.7% 7.0000UMIL VIAL 2 101.9383 124.6800 81.8% 5.1% 7.0000UMIL VIAL 2 101.9383 124.6800 80.7% 3.4%			2.5%	80.8%	37.4034	30.2195	თ	PROCRIT 3000UML VIAL	59676030301
Average Actual Acquisition Actual Acquisition Acquisition Acquisition Average Deviation Averag			3.4%	80.7%	249.3600	201,3450	7	PROCRIT 20000U/ML VIAL	59676032001
Average Average Average Average Average Average Average Acquisition Acquisition Acquisition Cost as% Standard DP (if Cost			5.1%	81.8%	124,6800	101.9383	2	PROCRIT 10000U/ML VIAL	59676031201
Average         Average         Average         Average           Actual         Acquisition         Acquisition         Cost as% Standard         DP (if Cost as% Standard           No. of Acquisition         Cost as% Standard         DP (if Cost as% Standard         DP (if Cost as% Standard           PROCARDIA XL 90MG TABLET SA         19         2.2817         2.8482         80.1%         1.0%         2.3985           PROCHLOAPERAZINE 10MG TAB         29         0.1130         0.8140         13.9%         2.4%           PROCHLOAPERAZINE 25MG SUPP         64         2.1192         2.9931         70.9%         6.1%			2.7%	81.7%	124.9712	102,1505	15	PROCRIT 10000U/ML VIAL	59676031001
Average Averag		•	6.1%	70.9%	2.9931	2.1192	64	PROCHLORPERAZINE 25MG SUPP	00713013512
Average Averag			2.4%	13.9%	0,8140	0.1130	29	PROCHLORPERAZINE 10MG TAB	62269027624
Average Averag	95.1%	2.3985	1.0%	80.1%	2.8482	2.2817	19	PROCARDIA XL 90MG TABLET SA	00069267066
Average	1	I	0	וד	m	D	0	СĐ	A
Average Average Actual Acquisition Acquisition Cost as % Standard DP (If	C	applicable	Deviation	of AWP	AWP	Cost.	Obs.		NDC Number
Average Acquisition	Cost as % of		Standard	Cost as %		Acquisition			
Average	Acquisition	4.0		acquisition		Actual			
	Agerava			Average		Average			

## Acquisition Cost Summary by Drug Top 200 Multi-Source Drug Products without an FUL Study of Medi-Cal Pharmacy Reimbursement

(Limited to Observations from External Invoices)

	1.1%	83.6%	0.9210	0.7701	142	ZESTRIL SMG TABLET	00340013010
	0.8%	83.5%	1.4941	1.2480	71	ZESTAIL 40MG TABLET	00310013410
	1.3%	83.2%	1.0181	0.8475	212	ZESTRIL 20MG TABLET	00310013210
	1.3%	83.3%	0.9497	0.7911	198	ZESTAIL 10MG TABLET	00310013110
0.9834	0.9%	80.4%	1.2293	0.9887	69	ZEBETA SMG TABLET	00005381638
	0.6%	83.8%	0.8068	0.6759	27	WELLBUTRIN 75MG TABLET	00173017755
	0.9%	84.1%	1.0730	0,9021	24	WELLBUTRIN 100MG TABLET	00173017855
	6.8%	46.6%	0.6368	0.2968	61	WARFARIN SODIUM 5MG TABLET	.00555083302
		79.7%	4.6883	3.7386	_	VIVONEX PEDIATRIC PACKET	00212713176
0.8728		80.0%	1.0910	0.8728	ω	VASOTEC SMG TABLET	00006071282
0.883	0.4%	80.2%	1,1040	0.8852	8.	VASOTEC SMG TABLET	00006071268
1.3182	0.5%	80.3%	1.6478	1.3227	65	VASOTEC 20MG TABLET	00006071468
0.6936	0.5%	80.0%	0.8670	0,6933	25	VASOTEC 25MG TABLET	00006001468
0,9164		80.0%	1.1456	0.9164	ယ	VASOTEC 10MG TABLET	00006071382
0.9306	0.6%	80.3%	1.1632	0.9335	10 8	VASOTEC 10MG TABLET	00006071368
	1.1%	84.1%	2.5752	2.1665	260	VANCERIC INHALER	00085073504
	0.9%	83.7%	6,6359	5.5513	87	VANCENASE 42MCG POCKETHALER	00085064902
	0.4%	80.2%	1.5119	1,2133	ಚ	ULTRASE MT 20 CAPSULE ÉC	58914000410
	1.2%	81.4%	0.0892	0.0725	<del>1</del>	TYLENOL EX-STR 500MG TABLET	00045049960
	0.6%	84.0%	0.0892	0.0749	ω	TYLENOL EX-STR 500MG GELCAP	00045046870
Œ	O	Ъŋ	ŧη	D	C	80	۵
				0	000	Leoco Fried	MAC MCUMPEL
applicable)	Deviation	of AWP	AWVO	<u>.</u>	7		
DP (st	Standard	Cost as %		Acquistion	ν ο		
		Acquisition		Actual			
		WARIOR	The second of the second	Wyelage			

CA\_EAC\_exhibits.xls [MSNF-By-Drug - AWP]

Myers and Stauffer LC

C: Number of invoice line items matched.

D: Average acquisition cost per unit observed in the Invoices.
 E: Average of May 2000 and November 2000 AWP per unit.

H: Average of May 2000 and November 2000 Direct Price (DP) per unit weighted by quantity purchased (if applicable). I: Average acquisition cost as % of DP.

F: Average acquisition cost as % of AWP.
G: Standard deviation of acquisition cost as a percent of AWP.

for each invoice line item.

weighted by quantity purchased

Explanation of Columns

A: National Drug Code Number

B: Product Description

#### (Limite Acquisition Cost Summary by Drug Top 200 Multi-Source Drug Products with an FUL Study of Medi-Cal Pharmacy Reimbursement

ed	
100	
Observation	
from	
External	
s from External Invoices)	

Acquired FUL Control of Control o	45.0%	0.0360	2.3%	10.0%	0.1669	0.0162	0	BENZTROPINE MES 1MG TABLET	49884016501
Adjustion  Adjust Adjus	37.3%	0.0360	3.1%	9.1%	0.1545	0.0134	σ <sub>0</sub>	BENZTROPINE MES 1MG TABLET	49884016510
Acetaminophemicod by Tablet 21 0.084 0.085 0.0875 Acetaminophemicod by Tablet 21 0.0884 0.0885 0.0885 0.0885 Acetaminophemicod by Tablet 32 0.0497 0.0281 2.12% 0.0875 Acetaminophemicod by Tablet 3 0.0497 0.0281 2.12% 0.0875 Acetaminophemicod by Tablet 3 0.0497 0.0281 2.12% 0.09% 0.0875 Acetaminophemicod by Tablet 3 0.0497 0.0281 2.12% 0.09% 0.0875 Acetaminophemicod by Tablet 3 0.0497 0.0281 2.12% 0.09% 0.0875 Acetaminophemicod by Tablet 3 0.0497 0.0281 2.12% 0.09% 0.0875 Acetaminophemicod by Tablet 3 0.0497 0.0281 2.12% 0.09% 0.0875 Acetaminophemicod by Tablet 1 0.02842 0.2416 0.2812 2.12% 0.09% 0.0875 Acetaminophemicod by Tablet 1 1 0.02842 0.2416 0.2812 2.12% 0.09% 0.0875 Acetaminophemicod by Tablet 1 1 0.02842 0.2416 0.2812 2.12% 0.09% 0.0875 Acetaminophemicod by Tablet 1 1 0.02842 0.2416 0.2812 2.12% 0.09% 0.0875 0.0070 0.0875 0.0875 0.0875 0.0875 0.09% 0.0985 0.0875 0.0070 0.0875 0.0875 0.0875 0.0875 0.09% 0.0985 0.0875 0.0070 0.0985 0	40.1%	0.0805	1.0%	8.7%	0.3706	0.0322	41	SACLOFEN 10MG TABLET	00172409660
Acetalisation   Average	40.8%	0.0800	0.7%	9.0%	0.3628	0.0326	31	BACLOFEN 10MG TABLET	00364231201
Acetaminophemicod state	42.9%	0.0435	0.0%	2.5%	0.7397	0.0187	8	ATENOLOL SOMG TABLET	00781150601
Acceptable   Acquisition   A	32.4%	0,0435	0.0%	1.8%	0.8050	0.0141	_	ATENOLOL SOMG TABLET	00378023110
Actival Acquisition  Description  Obs.  Cost  Acquisition  Acquisition  Cost Acquisition  FUL  Cost as % Standard  FUL  Cost as % Standard  FUL  Actival Acquisition  FUL  Actival Acquisition  Acquisition  Acquisition  FUL  Actival Acquisition  FUL  Cost as % Standard  Deviation  FUL  Cost as % Standard  Cost as % Deviation  FUL  Acquisition	30.2%	0.0435	0.3%	1.9%	0.6850	0.0132	46	ATENOLOL SOMG TABLET	00781150610
Application	58.5%	0.0413	1.8%	3.5%	0.7000	0.0242	29	ATENOLOL 25MG TABLET	00005321843
Acetaminophemicod batalett 21 0.2646 2.276 2.21% 3.8% 5.9% 0.0875 acetaminophemicod batalett 21 0.2646 2.276 2.21% 3.8% 0.0875 acetaminophemicod batalett 21 0.0684 0.2276 2.21% 0.0875 acetaminophemicod batalett 21 0.0684 0.2276 2.21% 0.0875 acetaminophemicod batalett 21 0.0684 0.2276 2.29% 0.09% 0.0875 acetaminophemicod batalett 21 0.2646 4.1293 5.9% 0.09% 0.0875 acetaminophemicod batalett 11 0.2642 4.2170 6.3% 0.09% 0.2686 acyclovin acomic tablett 11 0.2642 4.2170 6.3% 0.09% 0.2686 acyclovin acomic tablett 11 0.2642 4.2170 6.3% 0.09% 0.2686 acyclovin acomic tablett 11 0.2642 4.2170 6.3% 0.09% 0.2686 acyclovin acomic tablett 11 0.2642 4.2170 6.3% 0.09% 0.29% 0.29% albutance inmac tablett 11 0.2642 4.2170 6.3% 0.09% 0.29% 0.1990 albutance inmac inmac tablett 12 0.0044 0.0051 11.26% 0.09% 0.4394 albutance inmac inmac tablett 13 0.1462 1.2693 11.2693 12.09% 0.4394 albutance inmac inmac tablett 13 0.1618 1.2603 12.09% 0.0394 0.00111 amount inmac inmac in mac in machine inmac in machine in mach	42.5%	0.0413	0.0%	2.5%	0.7026	0.0176	117	ATENOLOL 25MG TABLET	00781107801
Average	44.4%	0.0595	0.0%	2.5%	1.0390	0.0264	62	ATENOLOL 100MG TABLET	00781150701
Averlage Acquisition  Acquisition  Acquisition  Acquisition  Acquisition  Acquisition  B  Cost  Cost  Acquisition  Acquisition  B  Cost  Acquisition  Awp  Ol Awp  Ol Awp  Deviation  FUL  Acquisition  Awp  Ol Awp  Deviation  FUL  Awp  Acquisition  Awp  Ol Awp  Deviation  FUL  Awp  Acquisition  Awp  Ol Awp  Deviation  FUL  Awp  Alguistion  FUL  Awp  Ol Awp  Deviation  FUL  Awp  Ol Awp  Deviation  FUL  Awp  Deviation  FUL  Awp  Ol Awp  Deviation  FUL  Awp  Ol Awp  Deviation  FUL  Awp  Alguistion  Awp  Ol Awp  Deviation  FUL  Awp  Ol Awp  Deviation  FUL  Awp  Ol Awp  Deviation  FUL  Awp  Deviation  FUL  Awp  Ol Awp  Deviation  FUL  Acquisition  Awp  Ol Awp  Deviation  FUL  Acquisition  Awp  Deviation  FUL  Full  F	61.4%	0.0185	9.4%	27.9%	0.0407	0.0114	Ž.	AMOXIL 250MG/5ML SUSPENSION	00029600922
Averlage Acquisition  Description  Description  Acquisition  Acquisition  Cost  Cost  Acquisition  Acquisition  B  C  D  Cost  Acquisition  Cost  Cost  Acquisition  Cost  Acquisition  B  C  D  E  F  G  Acquisition  Cost  Acquisition  Cost  Acquisition  FUL  Cost  Acquisition  FUL  Cost  Acquisition  FUL  Cost  Acquisition  Cost  Acquisition  FUL  Cost  Acquisition  FUL  Cost  Acquisition  FUL  Acquisition  FUL  Cost  Acquisition  FUL  Cost  Acquisition  FUL  Acquisition  FUL  Cost  Acquisition  FUL  Acquisition  FUL  Acquisition  FUL  Acquisition  FUL  Cost  Acquisition  FUL  Acquisition  Acquisition  FUL  Acquisition  FUL  Acquisition  FUL  Acquisition  Acquisition  FUL  Acquisition  Acquisition  FUL  Acquisition  Acquisitio	48.6%	0.0185	0.9%	19.0%	0,0474	0,0090	66	AMOXICILLIN 250MG/5ML SUSP	00093415580
Average	44.4%	0.1762	2.0%	21.4%	0.3658	0.0782	56	AMANTADINE 100MG CAPSULE	62269021124
Average Averag	100.9%	0,0111	18.0%	17.6%	0.0617	0.0112	ę	ALBUTEROL SULF 2MG/5ML SYRP	00093066116
Actual Average Average Average Average Average Average Average Actual Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Average Acquisition Average Acquisition By C Dys. Cost. Average Acquisition Average Acquisition By C Dys. Cost. Average Acquisition Average Acquisition Average Acquisition Average Acquisition Average Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition By C Dys. Cost. Acquisition Acquisit	39.7%	0.0111	0.0%	8.5%	0,0516	0.0044	57	ALBUTEROL SULF 2MG/5ML SYRP	59930151005
Acquisition	34.5%	0.4394	0.9%	12.0%	1,2603	0.1518	35	ALBUTEROL SOMOG INHALER	59772617502
Acquisition	43.0%	0.4394	4.0%	12.9%	1,4319	0.1891	134	ALBUTEROL SOMOG INHALER	00172439018
Actual   A	33.3%	0.4394	1.0%	11.6%	1.2594	0.1462	193	ALBUTEROL SOMOG INHALER	59930156001
Average Acquisition Cost as % Standard Cost as % Standard Cost as % Standard Acquisition FULL Description Obs. Cost Acquisition AWP of AWP Deviation. FULL Acquisition Description Obs. Cost as % Standard Could acquisition AWP observed Acquisition Full AWP Deviation. FULL Acquisition AWP Deviation FULL Acquisition Acqu	36.4%	0.1990	2.9%	18.0%	0.4033	0.0725	74	ALBUTEROL .83MG/M/L SOLUTION	49502069703
Average Acquisition Cost as % Standard Cost as % Standard Cost as % Standard Cost as % Standard Acquisition FULL Acquisition AWP of AWP Deviation FULL Acquisition Description Obs. Cost AWP of AWP Deviation FULL Acquisition AWP of AWP Deviation FULL B C D E F G H AWP Deviation FULL B C D STANDARD COST ACCT AMINOPHENICOD #3 TABLET 1 0.0495 0.2276 22.1% 3.6% 0.0975 ACCT AMINOPHENICOD #3 TABLET 3 0.0497 0.2034 24.4% 1.5% 0.0975 ACCT AMINOPHENICOD #3 TABLET 2 0.0555 0.2612 21.2% 0.0% 0.0875 ACCIDINA 400MG TABLET 2 0.0555 0.2612 21.2% 0.0% 0.0875 ACCIDINA 400MG TABLET 21 0.2416 4.1293 5.9% 0.3% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 0.0% 1.2680 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 0.0% 0.2666 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 0.0% 0.2666 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 0.0% 0.2666 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 0.0% 0.2666 ACCIDINA 400MG TABLET 1 0.2642 4.2170 6.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0	35.5%	0.1990	2.0%	17.5%	0.4033	0.0706	84	ALBUTEROL BOMG/ML SOLUTION	59930150008
Average   Standard   FUL   Average   Average   Standard   FUL   Average	34.5%	0.3150	5.0%	22.9%	0,4753	0.1087	58	AK-CON 0.1% EYE DROPS	17478021612
Average Average Acquisition Ac	17.9%	1.2680	0.5%	6.2%	3,6666	0.2275	17	ACYCLOVIR BOOMG TABLET	55953094740
Average Average Acyclovia and Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Acquisition Accordance Acyclovia Acyclovia accordance	20.8%	1.2680	0.0%	6.3%	4.2170	0.2642		ACYCLOVIR 800MG TABLET	00378030201
Average Average Acquisition Ac	19.1%	1.2680	0.3%	5.9%	4,1293	0.2416	21	ACYCLOVIR 800MG TABLET	00172426860
Average         Average         Average         Average         Average           Acquisition         Acquisition         Cost as % Standard         Standard         FUL           Description         Obs.         Cost         AWP         of AWP         Deviation         FUL           B         C         D         E         F         G         H           ACETAMINOPHEWCOD #3 TABLET         67         0.0495         0.2276         22.1%         0.0%         0.0875           ACETAMINOPHEWCOD #3 TABLET         1         0.0584         0.2450         27.9%         0.0%         0.0875           ACETAMINOPHEWCOD #3 TABLET         3         0.0497         0.2034         24.4%         1.5%         0.0875           ACETAMINOPHEWCOD #3 TABLET         2         0.0555         0.2512         21.2%         0.0%         0.0875	17.7%	0.6266	0.3%	5 9%	1.8860	0.1111	32	ACYCLOVIR 400MG TABLET	55953094340
Average Acetralion         Average Acetralion         Average Acetralion         Average Acetralion         Average Acetralion         Acetralion         Acetralion         Full           B         C         D         E         F         G         H           ACETAMINOPHEN/COD #3 TABLET         67         0.0495         0.2276         22.1%         3.6%         0.0875           ACETAMINOPHEN/COD #3 TABLET         1         0.0584         0.2450         27.9%         0.0%         0.0875           ACETAMINOPHEN/COD #3 TABLET         1         0.0584         0.2450         27.9%         0.0%         0.0875           ACETAMINOPHEN/COD #3 TABLET         1         0.0584         0.2450         27.9%         0.0%         0.0875           ACETAMINOPHEN/COD #3 TABLET         3         0.0497         0.2034         24.4%         1.5%         0.0875	63,4%	0.0875	0.0%	21.2%	0.2612	0.0555	2	ACETAMINOPHEN/COD #3 TABLET	00228302010
Average         Average <t< td=""><td>56.8%</td><td>0.0875</td><td>1.5%</td><td>24.4%</td><td>0.2034</td><td>0.0497</td><td>သ</td><td>ACETAMINOPHEN/COD #3 TABLET</td><td>51285030305</td></t<>	56.8%	0.0875	1.5%	24.4%	0.2034	0.0497	သ	ACETAMINOPHEN/COD #3 TABLET	51285030305
Average Averag	78.2%	0.0875	0.0%	27.9%	0.2450	0.0684	_	ACETAMINOPHEN/COD #3 TABLET	00093015001
Average Average Acquisition Acquisition Acquisition Acquisition Cost as % Standard FUL  Description Obs. Cost AWP of AWP Deviation FUL  B C D E F G H  ACETAMINOPHEWCOD #3 TABLET 67 0.0495 0.2276 22.1% 3.6% 0.0875	57.3%	0.0875	1.1%	21.0%	0.2391	0 0502	38	ACETAMINOPHEN/COD #3 TABLET	00228302096
Average Average Acquisition Acquisition Acquisition Cost as % Standard FUL  Bescription Obs. Cost AWP of AWP Deviation FUL  B C D E F G H	56.6%	0.0875	3.6%	22.1%	0.2276	0,0495	67	ACETAMINOPHEN/COD #3 TABLET	00093015010
Average Average Acquisition Acquisition Cost as % Standard No, of Acquisition Cost as % Standard No, of Acquisition AWP of AWP Deviation FUL		I	ଦ	נע	m	Ö	C	Co.	Þ
Average Average Average Acquisition Acquisition Acquisition No. of Acquisition Cost as % Standard Fill	c.	TOT	Devianon	OI AVVE	AWP	Cost	Obs.		NDC Number
Acquisition	COST BS 78		Standard	Cost as %		Acquisition			
	Acquisition		)	Acquisition		Actual			
				34000		Average			

CA\_EAC\_exhibits.xls [MSF-By-Drug - AWP&FUL]

### Acquisition Cost Summary by Drug Top 200 Multi-Source Drug Products with an FUL Study of Medi-Cal Pharmacy Reimbursement

(Limited to Observations from External Invoices)

BENZTROPINE MES 2MG TABLET BENZTROPINE MES 2MG TABLET CARBAMAZEPINE 100MG TABLET CARBAMAZEPINE 200MG TABLET CARBIDOPALEVO 25/100 TAB CARBURA CAPSULE CEPHALEXIN 250MG CAPSULE CEPHALEXIN 250MG CAPSULE CEPHALEXIN 300MG CAPSULE CEPHAL
BENZTROPINE MES 2MG TABLET  CARBAMAZEPINE 100MG TABLET  CARBAMAZEPINE 200MG CAPSULE  CARBAMAZEPINE 200MG CAPSULE  CEPHALEXIN 250MG CAP
2 2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

#### (Limited to Observations from External Invoices) Top 200 Multi-Source Drug Products with an FUL Acquisition Cost Summary by Drug Study of Medi-Cal Pharmacy Reimbursement

nted to O	nted to Observations from External Invoices)	alces)			
			Average Actual		Average Acquisition
C Number	Description	No. of A	Acquisition Cost	AWP	cost as %
Α-	Œ	0	٥	ľη	'n
B1203701	CLOMIPRAMINE SOMG CAPSULE	ත	0.1651	1,0646	15.5%
93083201	CLONAZEPAM 0.5MG TABLET	28	0.0478	0.7490	6.4%
28300311	CLONAZEPAM 0.5MG TABLET	46	0.0248	0.7552	3.3%
44074601	CLONAZEPAM 0.5MG TABLET	34	0.0371	0.7490	5.0%
28300350	CLONAZEPAM 0.5MG TABLET	4	0.0378	0.7106	5.3%
44074605	CLONAZEPAM 0.5MS TABLET	ယ	0.0862	0.7100	12.1%
37095205	CLONAZEPAM 0.5MG TABLET	2	0 0339	0.6424	5.3%
81178701	DICLOFENAC SOD 50MG TAB EC	41	0.1323	0.9068	14.5%
28255011	DICLOFENAC SOD SOME TABLEC	13	0.1089	0.9457	11.5%
81178901	DICLOFENAC SOD 75MG TAB EC	28	0.1350	1.0646	12.7%
1000		5		1 0113	101%

			Average		100,000			
			Actual		Acquisition	بنب		Acquisition
		No of A	Acquisition		Cost as %	Standard		Cost as %
NDC Number	Description	Obs.	Cost	AWP	of AWP	Deviation	FUL	ol +UL
b.	ĈD.	O	٥	IJ	ות	ົດ	I	
00781203701	CLOMIPRAMINE SOMS CAPSULE	on	0.1651	1,0646	15.5%	2.6%	0.7909	20.9%
00093083201	CLONAZEPAM 0.5MG TABLET	28	0.0478	0.7490	6.4%	0.9%	0.4145	11.5%
00228300311	CLDNAZEPAM 0.5MG TABLET	46	0.0248	0.7552	3.3%	0.8%	0.4146	6.0%
52544074601	CLONAZEPAM 0.5MG TABLET	34	0.0371	0.7490	5.0%	0.9%	0.4146	9.0%
00228300350	CLONAZEPAM 0.5MG TABLET	4	0.0378	0.7106	5.3%	0.6%	0.4146	9.1%
52544074605	CLONAZEPAM 0.5MG TABLET	ယ	0.0862	0.7100	12.1%	12.9%	0.4146	20.8%
62037095205	CLONAZEPAM 0.5MG TABLET	2	0 0339	0.6424	5.3%	0.0%	0.4146	%2.9
00781178701	DICLOFENAC SOD 50MG TAB EC	41	0.1323	0.9068	14.5%	1.0%	0.7490	14.7%
00228255011	DICLOFENAC SOD SOME TABLEC	13	0.1089	0.945/	13.7%	5.0%	0.7490	14.6%
00791178910	DICLOFERAC SOO TSUG TAR EC	10	0 1222	1.0113	12.1%	4.8%	0.9219	13.3%
007278255111	DICLOFENAC SOD 75MG TAB EC	28	0.0988	1.1447	8.6%	1.4%	0.9219	10.7%
59772605801	DICLOXACILLIN SOOMS CAPSULE	26	0.1317	0.7562	17.4%	3.5%	0.6585	20.0%
00555005905	DIPHENHYDRAMINE SOMG CAPS	12	0.0156	0.0276	56.5%	1.4%	0.0141	110.6%
00472136016	ENULOSE TOGM/15ML SYRUP	57	0.0078	0.0691	11.3%	4.9%	0.0228	34.2%
00555044523	ERYTHROMYCIN/SULFISOX SUSP	32	0.0387	0 1239	31.2%	5.7%	0.0883	00.0%
00555044521	ERYTHROMYCIN/SULFISOX SUSP	25	0.0356	0.1253	28.4%	3.9%	0.0/15	49.0%
00555044522	ERYTHROMYCIN/SULFISOX SUSP	13	0.0412	0.1270	32.4%	7.5%	0.0/46	30,7%
00093026492	FLUOCINONIDE 0.05% CINTMENT	38	0.1946	0.7668		* N.	0.5///	33.7%
00781143901	FLUPHENAZINE 10MG TABLET	ı a	0.1422	1.14/6	705.11	0.7%	0.3521	28 8%
00781143601	FEOTHERAZINE SMG CARSHI B	28 #	0.0620	0.3460	17.9%	3.2%	0.0675	91.9%
00378443005	FLURAZEPAM 30MG CAPSULE	12	0.0544	0.3375	16.1%	3.3%	0.0675	80.5%
00378020810	FUROSEMIDE 20MG TABLET	50	0.0131	0.1399	9.3%	3.0%	0.0210	62.2%
00781181810	FUROSEMIDE 20MG TABLET		0.0157	0.1228	12.8%	0.0%	0.0210	74.8%
00378021610	FUROSEMIDE 40MG TABLET	80	0.0159	0.1596	9.9%	2.6%	0.0254	47 FS/
00781196610	FURIOSEMIDE 40MG TABLET	4	0.0197	0.1403	14.0%	0.0%	0.0234	94 ло <sub>2</sub>
00378021601	FUROSEMIDE 40MG TABLET	3 13	0.0240	0.1630	% (۲۵)	- (. . (.)	0.0207	76.1%
003/8023201	FUNCSEMIDE SOME LABOR.	3 6	00000	0.707.0	83%	1.5%	0.1800	49.4%
00083067003	GEMPIBAUAIL OUUMG TABLET	2.0	0,0000					

Myers and Stauffer LC

### Acquisition Cost Summary by Drug Top 200 Multi-Source Drug Products with an FUL Study of Medi-Cal Pharmacy Reimbursement

(Limited to Observations from External Invoices)

			Average		Average			TAGE OF
			Actual		Acquisition			Acquisition
		No of	Acquisition		Cost as %	Standard		Cost as %
NDC Number	Description	100	Cost	AWP	of AWP	Deviation	FUE	01 FUL
<b>b</b>	מס	C	0	m	<b>`Y</b> 1	o.	I	~~
00047008430	GEMFJBROZIL 600MG TABLET	23	0.0718	0.9870	7.3%	0.3%	0.1800	39.9%
00047008420	GEMFIBROZIL 600MG TABLET	15	0.0663	0.9926	6.7%	0.0%	0.1800	36.8%
00093067006	GEMFIBROZIL 600MG TABLET	41	0.1108	1.2179	9.1%	2.0%	0.1800	61.5%
00781145310	GUPIZIDE 10MG TABLET	27	0.0279	0.5287	5,3%	0.4%	0.0930	30.0%
00781145301	GLIPIZIDE JOMG TABLET	30	0.0347	0.5850	5.9%	1.1%	0.0930	37.4%
00378111001	GUPIZIDE 10MG TABLET	1	0.0524	0.5976	8.8%	0.0%	0.0930	t6.3%
52544046105	GLIPIZIOE IOMO TABLET	10	0.0396	0.6070	6.5%	0.6%	0.0930	42.5%
00781145210	GLIPIZIDE SMG TABLET	22	0.0155	0.2883	5.4%	0.3%	0.0635	24.3%
00781145201	GLIPIZIDE SMG TABLET	24	0.0199	0.3186	6.3%	0.5%	0.0635	37.4%
52544046005	GLIPIZIDE SMG TABLET	7	0.0248	0.33//	7.4%	1.3%	0.0000	44.0%
59930162101	CHANGACING TABLET	2 5	0.2230	0.8720	14.9%	3.5%	0.6293	20.6%
023781:6001	GUANFACINE IMG TABLET	 	0.1503	0,8720	17.2%	7.9%	0.6293	23.9%
52544038705	HYDROCODONE/APAP 7,5/750 TB	103	0.0531	0.3640	14.6%	1.1%	0 1462	36.3%
00168008031	HYDROCORTISONE 2.5% CREAM	29	0.0816	0.2947	27.7%	3.6%	0.1420	57.5%
62269025024	HYDROXYCHLOROQUINE 200MG TB	28	0.1830	1.0836	16.9%	1.8%	0.7/63	23.6%
52544069801	HYDROXYCHLOROQUINE 200MG TB	37	0.1713	1.2320	13.9%	0.8%	0.7763	22.1%
00781155610	ISOSORBIDE ON 10MG TABLET	81	0.0048	0.0366	13.0%	1.0%	0,0188	25.3%
00245004015	KLOR-CON 8MEQ TABLET SA	18	0.0403	0.1741	23.1%	5.8%	0.0/65	52.7%
00245004011	KLOR-CON BMEQ TABLET SA	1	0.0383	0.1774	21.6%	6.0%	0.0765	50.1%
00781140305	LORAZEPAM 0.5MG TABLET	ço	0.0841	0.6252	13.4%	2.1%	0.5088	16 0%
00781140401	LORAZEPAM IMG TABLET	. 4	0.1628	0.83//	19.4%	) U.U.	0.0004	14.0%
00/81140410	CORACETAM ING LABORET	. c	0.0000	0.7007	129%	4 6%	0.6684	17.0%
000000000000000000000000000000000000000	- OBAZEDAM IMG TABLET	N 1	0.1060	0.8616	12.3%	0.0%	0 6684	15.9%
00378045705	LORAZEPAM 1MG TABLET	12	0.1261	0.8613	14.6%	6.5%	0.6684	18.9%
00378077701	LORAZEPAM 2MG TABLET	20	0.1561	1.2843	12.2%	5.4%	0.9910	10.0%
00781140501	LORAZEPAM 2MG TABLET	<b>U</b> n	0.1744	1.2211	14.3%	1.7%	0.66.0	74.0%
49884003510	MECLIZINE 25MG TABLET	19	0.0189	0.4570	41%	0,5%	0.0200	, t. V.
00555060702	MEGESTROL 40MG TABLET	26	0.2822	1.1021	20.6%	1,5%	0,0,0,	1

#### Acquisition Cost Summary by Drug (Limited to Observations from External Invoices) Study of Medi-Cal Pharmacy Reimbursement Top 200 Multi-Source Drug Products with an FUL

			Average		Average			Average
			Actual		Acquisition			Acquisition
	Ø • • • • • • • • • • • • • • • • • • •	200 100 100 100 100 100 100 100 100 100	Accuisition	QWA	of AWP	Deviation	- Ju	of FUL
ADC Montroot	000							
A	B	C	0	ľħ	ЪГ	0	Ι	*
49884029001	MEGESTROL 40MG TABLET	600	0.3109	1.2300	25.3%	4.9%	0.6707	46.4%
00555060704	MEGESTROL 40MG TABLET	⋈	0.2360	1.0588	22.3%	2.5%	0.6707	35.2%
49884029005	MEGESTROL 40MG TABLET	22	0.2481	1.0608	23.4%	1.6%	0.6707	37.0%
00406112201	METHYLIN IOMG TABLET	15	0.1997	0.4772	41.9%	3.2%	0.4023	49.6%
00364047901	METHYLPHENIDATE 10MG TABLET	-	0.1768	0.4770	37.1%	0.0%	0.4023	43.9%
59772884101	METHYLPHENIDATE 10MG TABLET	25	0.1553	0.4716	32.9%	10.0%	0.4023	38.6%
00364056101	METHYLPHENIDATE SMG TABLET	4	0.1811	0.3340	54.2%	9.4%	0.2677	62,9%
00378003210	METOPROLOL SOME TABLET	7	0 0222	0.5443	4.1%	0.8%	0.0645	34.5%
00781122310	METOPROLOL SOMG TABLET	20	0.0188	0.4866	3.9%	0.3%	0.0640	29.1%
00/8112/301	METOPROLOL SOMO TABLET	- E	0.0204	0.3110	5 9%	0.3%	0.2142	27.0%
00378045105	NAPROXEN SOOMG TABLET	æ	0,0691	1.1928	5.8%	0.0%	0.1823	37.9%
00781116505	NAPROXEN SOOMS TABLET	16	0.0789	1,1260	7.0%	0.4%	0.1823	43.3%
00781116510	NAPROXEN SOOMS TABLET	_	0.1011	0.9856	10 3%	0.0%	0.1823	55.5%
00781116501	NAPROXEN SOOMS TABLET	7	0.0841	1.1599	7 2%	0.6%	0.1823	46.1%
52544055228	NECON 1/35-28 TABLET	51	0.3920	0.9587	40.9%	2.8%	0.3828	102.4%
00172213160	MITROPURANTOIN MCR 100MG CP	31	0.3120	1.1785	26.5%	2.0%	0.8184	38.1%
00172213060	NITROFURANTOIN MCR SOMG CAP	27	0.1944	0.6778	28.7%	5.3%	0.5084	38.2%
00364250901	NORTRIPTYLINE HOL 25MG CAP	30	0.0398	0.8031	5.0%	0.4%	0.1496	26.6%
00364251001	NORTRIPTYLINE HCL 50MG CAP	22	0.0554	1.5180	3.7%	0.3%	0.1830	30.3%
50111045601	OXYBUTYNIN SMG TABLET	36	0.0403	0.3859	10.4%	2.3%	0.1463	2/5%
50111045603	OXYBUTYNIN SMG TABLET	ÇT	0.0333	0.3350	9.9%	1.6%	0.1463	22.7%
38245022520	POTASSIUM OL BMEQ TABLET SA	ហ	0.0338	0.1698	19.9%	1.3%	0.0765	44.2%
38245022510	POTASSIUM CL 8MEQ TABLET SA	<u>-</u>	0.0337	0.1716	19.6%	0.4%	0.0765	44.0%
61314063710	PREDNISOLONE AC 1% EYE DROP	50	0.9134	2.2000	41.5%	1.9%	1.6200	55.4%
61314063705	PREDNISOLONE AC 1% EYE DROP	40	0.9623	2,4060	40.0%	5.6%	1.8900	20.8%
00364046101	PREDNISONE 10MG TABLET	20	0.0239	9.0704	34.0%	388	0.0448	00.6%
00364044201	PREDNISONE 20MG TABLET	21	0.0403	0.1424	28.3%	2.4%	0.0720	. U. W.
00364021802	PREDNISONE SMG TABLET	17.	0.0107	0.0300	35.5%	0.0%	0.0240	64.13
00364036601	PRIMIDONE 250MG TABLET	24	0,1/31	8089.0	25.7%	0.3%	0.2010	01.0%

CA\_EAC\_exhibits.xls [MSF-By-Drug - AWP&FUL]

## Acquisition Cost Summary by Drug Top 200 Multi-Source Drug Products with an FUL Study of Medi-Cal Pharmacy Reimbursement (Limited to Observations from External Invoices)

	00472030180 TRIA	_	50111044101 TRA	_	_	_	٠,	00378501001 THIC		,	Ϊ.	_	Č			00093008905 sulf	24208067004 SULF	00781159901 SPIR	Ϋ́		•		_	-			O>		1001	<i>y</i>	NDC Number
FRIAMCINOLONE 0 1% CREAM	FRIAMCINOLONE 0.1% CREAM	TRAZODONÉ 150MG TABLET	TRAZODONE 150MG TABLET	RAZODONE 100MG TABLET	IMOLOL 0.5% EYE DROPS	IMOLOL 0.5% EYE DROPS	IMOLOL 0.5% EYE DAOPS	THIOTHIXENE 10MG CAPSULE	THIOTHIXENE 10MG CAPSULE	THEOPHYLLINE 300MG TAB SA	TEGRETOL 200MG TABLET	TEGRETOL 200MG TABLET	TEGRETOL 100MG TABLET CHEW	SULFATRIM SUSPENSION	SULFAMETHOXAZOLE/TMP DS TAB	SULFAMETHOXAZOLE/TMP DS TAB	SULFACETAMIDE 10% EYE DROPS	SPIRONOLACTONE 25MG TABLET	SPIRONOLACTONE 25MG TABLET	SPIRONOLACTONE 25MG TABLET	ROXICET 5/325 TABLET	PROMETHAZINE/CODEINE SYRUP	PROMETHAZINE/CODEINE SYRUP	PROMETHAZINE/CODEINE SYRUP	PROMETHAZINE W/OM SYRUP	PROMETHAZINE W/DM SYRUP	PROMETHAZINE 6.25MG/5ML SYR	PROCHLORPERAZINE 10MG TAB	PROCHLORPERAZINE 10MG TAB	(II	Description
173	35	14	10	28	23	76	57	4	9	ယ	2	38	14	58		_	76	2	17	51	16	90	31	122	31	98	55	~	44	0	No. of Ac
0.0182	0.0232	0.1236	0.1603	0.0546	0.5230	0.4135	0.3797	0.1248	0.0870	0.0272	0.4033	0.4050	0.2110	0.0087	0.0649	0.0791	0.0730	0.1212	0.0886	0.0974	0.0422	0.0094	0.0081	0.0079	0.0098	0.0066	0.0048	0.3900	0.0768	0	Actual Acquisition Cost
0.0638	0.0632	0.9850	0.9446	0.4100	3.3197	3.2153	3,2080	0.6500	0,6010	0.1900	0.4782	0.4839	0,2540	0.0359	0.8531	0.9032	0.2830	0.3924	0.4064	0.4150	0.2573	0.0364	0.0206	0.0370	0.0196	0.0221	0.0194	0.8950	0.8941	m	AWP
28 6%	36 8%	12.6%	17.0%	13.3%	15.8%	12.9%	11.8%	19.2%	14.5%	14.3%	84.3%	83.7%	83.1%	24.1%	7.6%	8.8%	25.7%	30.9%	21.8%	23.5%	16.4%	25.8%	39.3%	21.4%	49.9%	29.8%	24.9%	43.6%	8.6%	Ŧ	Acquisition Cost as % of AWP
0.6%	11.2%	0.3%	1.8%	0.3%	4.2%	2.3%	2.3%	6.1%	1.3%	2.3%	0.3%	0.8%	0.5%	2.1%	1.2%	1.1%	4.3%	0.0%	2.0%	2.1%	1.6%	0.0%	7.3%	1.6%	0.3%	8.8%	1.7%	0.0%	1.5%	<b>G</b>	Standard Deviation
0.0302	0.0302	0.4943	0 4943	0.0974	2.3100	1.5195	1.0250	0.3326	0.3326	0.0815	0.1275	0.1275	0.1467	0.0224	0.0893	0.0893	0.0969	0.3351	0.3351	0.3351	0.0825	0.0111	0.0111	0.0111	0.0103	0.0103	0.0078	0.8092	0.8092	I	<b>TUC</b>
60.4%	77.0%	25.0%	32.4%	56.0%	22.6%	27.2%	37.0%	37.5%	26.2%	33.3%	316.3%	317.6%	143.8%	38.6%	72.7%	88.6%	75.4%	36.2%	26.5%	29.1%	51.1%	84.5%	72.9%	71.2%	95.0%	63.9%	62.0%	48.2%	9.5%	1	Acquisition Cost as %

CA\_EAC\_exhibits.xls [MSF-By-Drug · AWP&FUL]

Myers and Stauffer LC

Ī

#### Study of Medi-Cal Pharmacy Reimbursement Top 200 Multi-Source Drug Products with an FUL Acquisition Cost Summary by Drug

(Limited to Observations from External Invoices)

İ									Ť
			Average   Actual		Average Acquisition			Average Acquisition	
		No of	Acquisition		Cost as %	Standard		Cost as %	
NDC Number	Description	Obs	Cost	AWP	of AWP	Deviation	FUL	of FUL	
2	D	)	>	'n	Ŧŧ	o	I:	<b>-</b>	
00168000480	TRIAMCINGLONE 0.1% CREAM	<b>4</b> :	0.0201	0.0673	29.8%	0.8%	0.0302	66.5%	
00781271510	TRIAMTERENE/HCTZ 50/25 CAP	14	0.0267	0.2690	9.5%	1.5%	0.1350	19.8%	
00781254010	TRIAMTERENE/HCTZ 50/25 CAP	7	0.0290	0.2690	10.8%	1.8%	0.1350	21.5%	
00781271501	THIAMTERENE/HCTZ 50/25 CAP	34	0.0279	0.2796	10.0%	1.9%	0.1350	20.7%	
00781254001	TRIAMTERENE/HCTZ 50/25 CAP	8	0.0336	0.2796	12.0%	2.7%	0, 1350	24.9%	
59762371804	TRIAZOLAM 0.25MG TABLET	30	0.1770	0.7060	25.1%	6.8%	0.5286	33.5%	
00781103601	TRIFLUOPERAZINE 10MG TABLET	=	0.1696	1.5224	11.1%	2.2%	0.7133	23.8%	
00781103201	TRIFLUOPERAZINE 2MG TABLET	9	0.1305	0.8024	16.3%	1.8%	0.4683	27.9%	
00781103401	TRIFLUOPERAZINE SMG TABLET	16	0,1536	1.0098	15.2%	1.9%	0.5631	27.3%	
00003173745	TRIMOX 125MG/5ML SUSPENSION	51	0.0062	0.0274	22.7%	2.3%	0.0129	48.2%	_
00003010160	TRIMOX 250MG CAPSULE	15	0.0271	0.2370	11.4%	1.5%	0.0735	36.9%	_
00003173845	TRIMOX 250MG/5ML SUSPENSION	195	0.0088	0.0471	18.6%	2.1%	0.0185	47.5%	_
60432062116	VALPROIC ACID 250MG/5ML SYR	3 <u>4</u>	0.0210	0.1506	14.0%	3,0%	0.0594	35.3%	_
38245063307	VALPROIC ACID 250MG/SML SYR	V)	0.0208	0.1516	13.7%	0.0%	0.0594	35.0%	
00003011675	VEETIDS SOOMS TABLET	:6	0.0289	0,0968	29.9%	1.5%	0.0818	35.3%	_
000003011650	VEETIDS SOME TABLET	ផ	0.0349	0.1356	25.8%	6.2%	0.0818	42.7%	
00172428660	VERAPAMIL 180MG TABLET SA	52	0.1022	1.1100	9.2%	1.6%	0.2878	35.7%	
00172428070	VERAPAMIL 240MG TABLET SA	23	0.0882	1,1966	7.4%	0.6%	0.3113	28.3%	_
00172428060	VERAPAMIL 240MG TABLET SA	57	0.0941	1.2583	7.5%	1.2%	0.3113	30.2%	
00378041105	VERAPAMIL 240MG TABLET SA	2	0.0964	1.2316	7.8%	0.5%	0.3113	31.0%	_

#### Explanation of Columns A: National Drug Code Number

B: Product Description

C: Number of invoice line items matched.

E: Average of May 2000 and November 2000 AWP per unit weighted by quantity purchased D: Average acquisition cost per unit observed in the invoices

Myers and Stauffer LC

F: Average acquisition cost as % of AWP.
G: Standard deviation of acquisition cost as a percent of AWP.

H: Average of May 2000 and November 2000 Federal Upper for each invoice line item.

I: Average acquisition cost as % of FUL. Limit (FUL) per unit weighted by quantity purchased.

CA\_EAC\_exhibits.xls [MSF-By-Drug - AWP&FUL]

Exhibit 7

Acquisition Cost Summary by Drug Labeler (as a Percent of the AWP)
Single Source Drug Products - Top 30 Labelers Based on Medi-Cal Payments
Study of Medi-Cal Pharmacy Reimbursement

(Limited to Observations from External Invoices and Non-Direct Price Manufacturers)

				Mean	
				Acquisition Cost as	
			Atomakan of	Percentage of	Standard
	Labler	Number	Number of	~	Deviation
Labler	Code	of Drugs	Observations	the AWP	Deviation
ELI LILLY & CO.	00002	19	1,024	82.1%	3.4%
SK BEECHAM PHAR	00007	39	2,838	80.7%	1.8%
PHARMACIA/UPJHN	00013	22	967	79.8%	0.6%
G.D. SEARLE CO	00025	16	1,729	83.7%	0.3%
BAYER,PHARM DIV	00026	15	835	80.6%	6.1%
ROCHE LABS.	00029	23	403	82.2%	5.0%
MC NEIL	00045	11	535	83.3%	0.3%
ORGANON PHARM.	00052	6	392	83.1%	1.0%
ROXANE LABS.	00054	9	78	80.0%	3.4%
DU PONT PHARMA	00056	1	51	83.9%	0.0%
ORTHO PHARM.	00062	12	762	83.7%	0.3%
ALCON LABS.	00065	17	1,075	80.6%	0.6%
RHON-POUL RORER	00075	10	566	80.0%	2.0%
INOVARTIS	00078	39	2,460	82.9%	1.4%
SCHERING CORP.	00085	24	2,137	84.3%	1.2%
BMS PRIMARYCARE	00087	26	2,748	82.6%	1.2%
IBMS PRIMARYCARE	00087	26	2,748	82.6%	1.2%
HOECHST MAR ROU	00088	12	733	83.5%	0.3%
GLAXO PHARM	00173	31	1,387	83.6%	0.5%
ASTRA PHARM.	00186	17	1,338	83.3%	0.5%
TAP PHARM.	00300	9	711	81.6%	1.9%
ZENECA INC.	00310	14	690	81.7%	4.3%
FOREST PHARM	00456	14	594	79.0%	3.0%
BOEHRINGER ING.	00597	11	894	83.1%	0.8%
DISTA LABS.	00777	6	640	83.8%	0.8%
SERONO INC	44087	<u></u>	4		0.0%
JANSSEN PHARM.	50458	24	1,150	83.2%	0.5%
IMMUNEX CORP	58406	2	26		0.4%
PURDUE PHARMA L	59011	5	171		0.4%
TAKEDA PHARM	64764	6	313		0.0%
Total - All Labelers		796	43,218		2.8%

Myers and Stauffer LC

CA\_EAC\_exhibits.xls [Direct Price - By Labeler]

#### Exhibit 8

### Study of Medi-Cal Pharmacy Reimbursement Single Source Drug Products with a Direct Price Acquisition Cost Summary by Drug Labeler (as a Percent of the Direct Price)

(Limited to Observations from External Invoices)

				THE STATE OF THE S			_
				Acquisition		Approximate	Approximate
				Cost as		Percentage of	Percentage of
				Percentage of		Medi-Cal	Single Source
	Labler	Number	Number of	the Direct	Standard	Pharmacy	Direct Price
Labler	Code	of Drugs	of Drugs Observations	Price	Deviation	Payments	<b>Drug Payments</b>
ER Squibb and Sons Inc.	00003	9	664	98.3%	2.7%	1.7%	11.3%
Lederle Pharmaceutical	00005	Ç5	60	100.4%	0.4%	0.0%	0.2%
Merck and Co Inc.	00006	57	2,763	100.8%	3.0%	5.1%	33.6%
Wyeth Ayerst Pharmaceuticals Inc.	80000		477	100.2%	0.3%		2.8%
Pharmacia and Upjohn Co.	00009	16	491	99.9%	3.9%	0.3%	
Roerig Div. of Pfizer Inc.	00049	9	659	94.9%	0.3%		3.9%
Pfizer Laboratories	00069	16	1,404	95.0%	2.4%	1.8%	11.8%
Parke-Davis and Company	00071	19	2,422	87.6%	0.8%	3.2%	
Abbot Laboratories	00074	12	754	94.9%	2.1%	2.0%	13.4%
Total		151	9,694	97.4%	5.1%	15.1%	100.0%

# Pharmacy Acquisition Cost Survey Data Statistical Summary of Acquisition Costs as a Percent of the Average Wholesale Price Single Source Drug Products Study of Medi-Cal Pharmacy Reimbursement

	1174 6613011					ĺ						
								Daroantil es		95% Confid	95% Confidence Interval for Mean (based on Student f)	u for Mean
			General Statistics	islics				Clock the		. (200		
		n: Number of							· .:::			
		Phormacies /		Mean (Weighted		Standard				Ġ.	1.3	VOICE (NIX)
	Number of	٠. أ.	Mean	by Medicaid	Standard Er	ror of Ine					apper :	of franchism)
Characteristic	Observations	Products	(Unweighted) E	Drug Utilization)	Deviation	Mean	20%	50%	90%	Delition	popular of recogniti	n Heedern)
Distributions by Pharmacy	٠ <u>٠</u>											
Single Source Drug Products (as % of the Average Wholesale Price) - Includes internal Invoices	the Average Whole	sale Price -	Includes interna	s Invoices						<u>;</u>	3	· >
All Pharmacies	137,230	487	83.5%	S • Noi • (1)	%E 1	0.1%	82 4%	83.3%	865 78	83.4%	83.6%	. 40
Single Source Prug Products (as % of the Average Wholesale Price) - External Involces Only	the Average Whole	sale Price) -	External Involve	기타이 함								1
Institutional and Retail	43,218	272	82 8%	Saa Note (1)	1.29	01%	62 1%	82.8%	42 / %	02.1%	03.0%	
Institutional	2.804	18	82 1%	Soo Note (1)	1.4%	0.3%	81.0%	61.7%	05.0%	0.4	0.00%	
Retail	40,414	254	82 5%	See Note (1)	1.1%	0.0	82.2%	82.8%	83 /%	62.8%	04.U%	97
Single Source Orug Products (as % of the Average Wholesale Price) - Retail Pharmacies Only - External Invoices Only	the Average Whole	sale Price) -	Retail Pharmaci	es Only - Extern	al avoices Only							1 2 1
Chain	9,789	28	82.1%	See Note (1)	0.6%		81 5%	82 1%	82.2%	61.8	62.3%	2.08
Independent	30,625	226	83.0%	See Note (1)	1 1%	0.1%	82 3%	82.9%	83.8%	82,9%	681%	1.97
Grban (in-state only)	31,472	217	62.5%	San Note (1)	1.10	01%	82 3%	82 9%	83.8%	82.8%	2,1%	
Rural (In-state only)	6,942	37	62.6%	Sou Note (1)	1 3%	0.2%	82 3%	B2.3%	831%	82.2%	83 1%	2.03
Distributions by Drug Product <sup>2</sup>	luct <sup>2</sup>											
Single Source Drug Products 198 % or the Average wholesain Fine: - Citeties invoices Only All Pharmacies 796 81.7%	10e Average whole	- 7=01.4 alless	81.7%	82.4%	2.8%	0.1%	80:1%	82.6%	63.7%	81.5%	81 9%	1.98
Institutional Pharmacies	2,804	493	80.5%	81.7%		0.2%	79.3%	80.8%	83.3%	80.1%	80.9%	
Retall Pharmecies	40,414	776	8: 9%	82.5%		0.1%	80.2%	83.0%	83.7%	81 7%	82 + %	1.96
Chain Reteil Pharmacies	9,789	603	51.4%	81 9%		01%	79.6%	92.5%	83.0%		61.5%	
Independent Retail Pharmacies	30,525	767	62.1%	82.7%	27	C.1%	80.4%	83 2%	84 U%		62 3%	q
	a description of the second	Taken basses	ac distributions o	Cold and utilization. Including distributions of accretistion cost by store are not weighted	the store are por	wainhiad						

<sup>1)</sup> Individual store means are weighted by Medi-Cal drug utilization, however, distributions of ecquisition cost by store are not weighted.
2) Individual drug means are not weighted, however, the mean of the distribution of accursition cost by drug resulting from a weighted calculation is presented.

CAAG/DHS0068636

ļ

# Pharmacy Acquisition Cost Survey Data Statistical Summary of Acquisition Costs as a Percent of the Average Wholesale Price Single Source Drug Products not Paid with a Direct Price study of Medi-Cal Pharmacy Reimbursement

China and a standard of the company the	TITO PITO PITO											
			Genera Stalistics	sia			Pe	Percentiles		95% Confide (base	6 Confidence interval for (based on Student t)	95% Confidence Interval for Mean: (based on Student t)
		n: Number of Pharmacles/	<b>.</b>	Mean (Weighted Standard From of the	Sie Sie	Standard			4 (.).	Lower.	Upper	r Value (with
Characteristic	Observations 9		[Unweighted] Di	Drug Utilization) Deviation Mean	Deviation h	a an	20%	50%	80%	Bound	Bound	of Ireacom)
Distributions by Pharmacy!  Since Source Drug Products not Paid with a Direct Price (as % of the Average Wholesale Price) - Includes Internal Invoices.	with a Direct Price (	as % of the Av	erege Wholes	ale Pries) - Includ	es internal inve	ion.					:	
All Pharmacies	104,732	482	E4.0%	See None (1)	1.2%	C. 1%	62.5%	83.9%	85.4%	839%	841%	
Single Source Drug Products not Paid with a Direct Price (as, % of the Average Wholessie Price) - External Invoices Only	with a Direct Price (	as % of the Av	erage Wholes	sle Price) - Extern	al Invoices On			3	, ,	3 3 3 6	n h o	. 05
Institutional and Retail	33,524	267	633%	Same Note (1)	y iv	9 5	84.0%	80 0% 80 0%	B 2 2 2 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	81.7%	82 9%	2.1
institutional	2,101	3 4 9	63.4%	See Note (1)		ب ا پور	82.7%	63,3%	842%	63 3%	83.5%	1 97
Single Source Drug Products not Paid with a Direct Price (as % of the Average Wholegate Price) - Retail Pharmacies Only - External Invoices Only.	with a Direct Price (	is % of the Av	erage Wholes	ale Price) - Retail	Phermacies Or	lly - Exte	nel invoices Or	ξ				1
Chain	7,363	26	82 5%	See Note (1)	0 6%	01%	82.1%	82.5%	82.7%	32.4%	82.9%	205
Independent	23,960	221	83.5%	See Note (1)	1.1%	0.1%	62.8%	89.4%	84 3%	2000	03.7%	0 9 7
Urben (in-state only)	24,518	212	63.5%	See Mate (1)	1 1 1	9 9	02.730	2 4 4	20.00	62.7%	5 C C C C C C C C C C C C C C C C C C C	3
Rural (१ग-इtate only)	6,825	37	631%	See Note (1)	1.3%	0.2%	e2.5%	82.9%	α 4.	PK / %	0 0	8
Distributions by Drug Product?	uct <sup>2</sup>	on a second that do	retage Wholes	ale Price) - Extern	nat Invoices On	₹						
All Pharmacies	33,524	6.4	320%	82.5%	2.9%	01%	80.2%	63.2%	63,7%	81.7%	2.7.29	1,35
Institutional Pharmacies	2,181	398	80.7%	82.1%	4 6%	0.2%	/9 5%	0.7%	0 (4 (4 (4 (4 (4 (4 (4 (4 (4 (4 (4 (4 (4		20 - 60	1.0
Retail Pharmacies	31,343 343	629	82.2%	83 0%	2.8%	01%	80.3%	1 4 %	63.6%	07.0%	202.40	1 96
Chain Retail Pharmecies	7,383	479	81.7%	62.4%	2.1%	9	29.7%	02.7%	1 d d d d d d d d d d d d d d d d d d d	61.0%	0 . u	9, 9
Independent Relail Pharmacies	23,960	620	823%	83.2%	97 00		50 3%	0	2.0	6	6	; ;
	increal by Mark. Cal door with action, however distributions of acquisition cost by store are not weighted	elion however	distributions of	d Isos nomenimos	A JOU GIR STOLE	eighteo						
						2						

1) Individual store means are weighted by Medi-Cal drug utilization, nowever, distributions of sequisition cost by sister are not weighted accuration is presented 2) Individual drug means are not weighted calculation is presented

4,29,02

# Pharmacy Acquisition Cost Survey Data Statistical Summary of Acquisition Costs as a Percent of the Average Wholesale Price Single Source Drug Products Paid with a Direct Price Study of Medi-Cal Pharmacy Reimbursement

									:	95% Confidence interval for Mean	nce interv	al for Mean
			General Statistics	listics		1 1	9	Percentiles		(baset	(based on Student t)	ent t)
									: 			
	70	n: Number of										
	79	Pharmacles /		Mean (Weighted		Standard						United Solitor
	Number of	Products (	Mean Jawelahted)	Products (Unweighted) Drug Utilization Deviation	Standard Erk	Error of the	20%	50%	80%	Bound	Bound	of (reedom)
Distributions by Pharmacy										-		
Single Source Drug Products Peid with a Direct Price (as % of the Average Wholesele Price) - includes internal involces	a Direct Price (es	% of the Aver	age Wholesele	Price) - Includes	Internal Involce	•				2	2	2
All Pharmacles	32,498	480	82.1%	See Note [1]	1.3%	0.1%	0.0 30	0 1	92.9	82.0%	3%	: 9
Single Source Drug Products Paid with a Direct Price (as. % of the Average Wholesale Price) - External Invoices Only	a Direct Price (as	% of the Aver	age Wholesale	Price) - Externat	Invoices Only							
Institutional and Retail	9,694	265	81.5%	S & Note (1)	1 2%	0.1%	80.7%	81.3%	B2 5%	61.4%	B1 7%	1 97
Institutional	623	£.	80.5%	Son Note (1)	2 3%	0.5%	78.9%	79.7%	81 9%		61.60%	211
Retail	9,071	247	81.6%	See Nate (1)	1.3%	0.1%	60.7%	81.4%	B2.5%	81.5%	61.7%	1.97
Single Source Drug Products Paid with a Direct Price (as % of the Average Wholesale Price) - Betail Pharmacles Only	a Direct Price (as	% of the Ayer	age Wholesole	Pricet - Retail Ph	armacles Only	External	nva					· :
Chain	2,406	12 12 13	80.8%	See Note (1)	977.0	0.1%	80.2%	808%	61.0%	80.5%	61.0%	8
Independent	6,665	219	81.7%	See Note (1)	11%	0.1%	80.8%	81.5%	82.5%		61.8%	1.6
Urban (in-state enty)	6,954	210	8: 6%	See Note (1)	3.0%	01%	%3.08	81 4%	82 5%		81.8%	197
Rural (In-state only)	2,117	37	81,4%	Sas Note (1)	1 4%	0.2%	90.6%	80.8%	82.0%	e0.9%	69 60 80	2 03
Distributions by Drug Product <sup>2</sup>	Ct <sup>2</sup>											
Single Source Drug Products Paid with a Direct Price (as % of the Average Whotesale Price) - External Invoices Only all Pharmanies 80.9% 1.4%	a Direct Price (as 9 694	% of the Aver	%9 06 Jessycel W abt	%e.oa 	Invoices Only	0.1%	799%	80.2%	80.5%	80.4%	60,8%	1.98
Institutional Pharmacies	623	9	79 8%	80.2%	2.0%	0.2%	79.0%	80.0%	80.5%	79.4%	90.2%	1.96
Retail Pharmacies	9,071	:60	80.7%	%6.08	1.4%	0.1%	%C.08	80.2%	80.9%		30 9%	1.98
Chain Retail Pharmacles	2,406	126	80.1%	80 3%	1.2%	0.1%	79.4%	79.6%	79.8%		BO.3%	1.98
Independent Relail Pharmacies	6,665	149	60.9%	81.1%	1.5%	. 1%	80.2%	80.5%	81.2%	80.7%	81.2%	192. r
	Call de la citation	nation bowers	diese in those	an house and distributions of accretion ones but store are not weighted	hu close ere not u	ainte d						

1) individual store means are weighted by Medi-Cal drug utilization, however, distributions of acquisition cost by store are not weighted.
2) individual drug means are not weighted, however, the mean of the distribution of acquisition cost by drug resulting from a weighted calculation is presented.

Myers and Stauffer LC

# Pharmacy Acquisition Cost Survey Data Statistical Summary of Acquisition Costs as a Percent of the Average Wholesale Price Multi-Source Drug Products without an FUL Study of Medi-Cal Pharmacy Reimbursement

Cition of Supplies and Thairmack the	TO COLOR INC.											-
			General Statistics	2				Percentiles		95% Contid	85% Confidence Interval for Mean (based on Student t)	al for Mean nt t)
	), i	n; Number of										
	Number of	9 . 3 5	Mean	Mean (Weighted by Medicald	Standard E	Standard Error of the				Lower	Opper	n-1 degrees
Characteristic	Observations	Products (Un	weighted) Di	(Unweighted) : Crug.Utilization) : Deviation	- 1	Mean	20%	50%	80%	Bound	Bound of freedom)	of treedom)
Distributions by Pharmacy	<b></b>											
Muni-Sourge Drug Products without on FUL las % of the Average Wholesale Drice) - includes Internal Involces	FUL as % of the	Average Wholes	ate Price) - in	ciudes internal li	nvolces	i 		2	<b>!</b>	3	9	
All Pharmacies	49,260	488	64.0%	See Note (1)	\$1 E	04%	5/4%	64.3%	70.4%	0.7 5.0	0,6	. 90
Multi-Source Drug Products without on FUL (as % of the Average Wholesale Price) - External Invoices Only	FUL (as % of the	Average Wholes	ale Price) - Ex	dernal invoices.	•				!	<u> </u>	<u>:</u>	}
Institutional and Retail	14.704	273	64.6%	See Note (1)		0 78	57.0%	65.3%	72 4%	63.4%	65.9%	3.97
Inetitutional	1,108	á	57.0%	Spe Note (1)	10,9%	3 0 %	444	000	100.4	10000	0 1 2 2 2	1 07
Multi-Squrce Drug Products without en FUL (as % of the Average Wholessig Price) - Retail Pharmacies Only -External involces Only.	n FUL (as % of the	Average Wholes	ale Príce) - Au	toil Phagnecies	Only - Extern	lel fovolces C	April					
Chain	3,545	29	60.9%	See Note (1)	8.5%	. 6%	52.0%	50.0%	68.2%	57.6%	64.1%	205
independent	10,051	227	65.7%	See Note (1)	10.2%	0 7%	58.9%	55.4%	73.8%	54 4%	671%	19/
Urban (In-state only)	10,948	218	65.3%	See Note (1)	10 4%	0.7%	57.6%	66 0%	73 3%	63.9%	96.7%	1 9/
Aural (In-state only)	2,648	37	64.5%	Sed Note (1)	8.4%	1 4%	55 1%	64.6%	70.4%	61 8%	67.9%	2 03
Distributions by Drug Product <sup>2</sup>	uct <sup>2</sup>											
Multi-Source Drug Products without an FUL (as % of the Average Wholesele Price) - External Invoices Only	n FUL (as % of the	Average Wholes	(ale Price) - E)	dernaj Invoices	•		2 70/	j.	5	45 50	78 Ce/	1 0 0
All Profitations	3 3	3 6	2	20.00	2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	100	1600	44 69	80.0%	43 90°	49 9%	1.97
insututional Pharmacies	1,100	250	40.000	64 he/6	3 F	10.	1200	43.50	80 F	43.7%	47 A%	1.98
Drain Datail Dhamarian	3 CAP	A 9	47.6%	26 55 20 55 20 50 20 50	28.0%	4%	14.5%	49.3%	79.6%	45.1%	50.6%	1,97
Independent Retail Pharmacies	10.051	514	46.6%	58.2%	28.8%	2%	14.7%	44 1%	80.5%	44 3%	48 9%	1 96
1) Individual store means are weighted by Medi-Cel drug utilization, however, distributions of acquisition cost by store are not weighted	v Medi-Cal drug util	izalion, however,	distributions of	acquisition cost &	on are protected	l weighted						
		FC. C		TO COLLEGE COCCE	A							

nativatial store means are weighted by Mechical and utilization, however, distinctions of acquisition cost by store are not weighted, however, the mean of the distribution of acquisition cost by drug resulting from a weighted calculation is presented.

# Pharmacy Acquisition Cost Survey Data Statistical Summary of Acquisition Costs as a Percent of the Average Wholesale Price Multi-Source Drug Products with an FUL study of Medi-Cal Pharmacy Reimbursement

			General Statistics	stick x				Percentiles		95% Confid (base	95% Confidence Interval for Mean (based on Student t)	l for Mean ( /)
		n: Number of										
	Number of	Pharmacles/ Mean		Mean (Weighled by Medicald	Standard Err	Standard Error of the				Lower	Lower Upper n-1 degrees	n-1 degrees
Characterts(lo	Observations Products		weighted) Di	(Unweighted) Drug Uttlization) Deviation		Mean	20%	50%	80%	Bound Bound	Bound o	of freedom)
Distributions by Pharmacy	_											
Multi-Source Drug Products with an Full (as % of the Average Wholesale Price) - Includes Internal Invoices All Pharmacies 24,966 473 14,5% See Now (1)	L(as % of the Ave 24,966	<u>gaga Wholesala</u> 473	Price) - Includ	See Note (1)	6.1%	0 3%	11,0%	19.0%	17.5%	.41%	15.2%	1.97
Allelinguists Diving Boodings with an Ell (see % of the Average Wholerele Drive) (External Involves Only	(ac of of the Ave		· Drice) - Eyter	nai Invoinne Only								
Institutional and Retail	6,428	258	14.1%	Seq Note (1)	5.6%	0.4%	10.6%	13.1%	16.6%		14.9%	1.97
Institutional	460	17	%es;	San Nam (1)	5.4%	.3%	9.4%	12.4%	16.0%	11.1%	18.7%	2.12
Retail	5,966	241	£ : \$	See Note (1)	o 7%	0.4%	10,6%	i 31%	16.6%		15.0%	9
Multi-Source Drug Products with an FUL (as % of the Average Wholesale Price) - Retell Phermocies Only - External Invoices Only	Lies % of the Ave	rage Wholesale	Price) - Retal	LPhermecies Onli	( - Externel In	oices On	K					
Chain	1,637	28	:3.5%	See Note (1)	2.6%	0.5%		12.7%	15.2%	12.6%	14.6%	2.06
independent	4,321	213	14.2%	See Note (1)	7.1%	0.5%	10.5%	13.2%	17.0%		15.2%	1.97
Urban (in-state only)	4,886	205	13.9%	See Note (1)	6.6%	0.5%	10.5%	13.0%	16.4%		14.8%	1 97
Rural (In-state only)	1.082	ઝુ	15.5%	See Non (1)	5.5%	1.1%	11.9%	13.7%	17.4%	193%	17.7%	2.03
Distributions by Drug Product <sup>2</sup>	uct²							,			,	
Multi-Source Drug Pladucts with an FUL (as % of the Average Wholesole Price) - External Invoices Only	L (as % of the Ave	rage Wholesole	Price) - Exter	nal Invoices Only	•	į.	1	12	) J		10.18	
All Pharmacies	6,420	3 6	17.076	4 6 6 6	1 1 1	7 2	1 . v	11 2%	21.0	108%	5 4 5	1 98
Detail observed a survival of	5 GG G	3 1	175%	12.7%	4 2 1	%6.0	7.0%	13.3%	25.8%		19.4%	197
Chain Retail Phermacies	1,537	180	18.8%	13.5%	15,0%	- %	7 2%	14.5%	25.6%		21 0%	197
Independent Retail Pharmacies	4.331	226	17.5%	12.6%	14.3%	0.9%	7 0%	13 3%	26.0%	157%	19.5%	1 97
			,									
t) Individual store means are neighted by Med-Cel drug utilization, nowever, distributions of acquisition cost by store are not weighted	Medi-Cal drug utili	zation, nowaver,	distributions of	acquisition cost by	Store are not	veighted						

2) Individual drug means are not weighted, however, the mean of the distribution of acquisition cost by drug resulting from a weighted calculation is plasserted.

# Pharmacy Acquisition Cost Survey Data Statistical Summary of Acquisition Costs as a Percent of the Average Wholesale Price Multi-Source Drug Products without an FUL and not Paid with a Direct Price study of Medi-Call Pharmacy Reimbursement

Clock of Medical Cartiforniary are	PINCH SCHOOL											
			General Statistics	Ž			•	Percentiles		95% Confid	95% Confidence Interval for Meon (based on Student I)	al for Meen
	TO P.	n: Number of Pharmacles /		Mean (Weighted	2 X	Standard						f Value (with
Characteristic	Observations	Products (L	(Unweighted)	Drug Utilization)	Deviation	Mean	20%	50%	80%	Bound	Bound Bound of freedom	of freedom)
Distributions by Pharmacy	-											
Multi-Source Drug Products without an EUL and not Paid with a Direct Price (as % of the Average Wholesale Price) - Includes internal Involces	FUL and not Paid	with a Direct	Price (as % of	the Average Wh	otesale Prise)	Includes In	ternal invoice:	1	2	5	e e	
All Pharmacies	44,668	482	59.6%	S Note (1)	9.8%	0 4%	52.6%	59.2%	55.4%	08.7%	bU.4%	1.95
Multi-Source, Drug Products without an EUL and not Pold with a Direct Price (see % of the Average Whotesale Price) - Externel Investes Only	LEUL and not Peid	with a Direct	Price (es % of	the Average Wh	otesale Price) -	Externel in	Voices Only					
Institutional and Retail	13,026	267	60.9%	See Note (1)	12:0%	0.7%	51.6%	60.5%	70.0%	58.9%	61.7%	1.97
Institutional	956	*	530%	Sas Note (1)	10.7%	5/76	S U N	O# 0.40	00.076	6	6	. h
netail	12,080	249	608%	Seo Non (1)	11 5%	0.7%	52.0%	61.2%	70 0%	59 4%	6Z 3%	1.4
Multi-Source Orig Products without an FUL and not Paid with a Direct	FUL and not Paid		Price (es % of	Price (as % of the Average Wholesale Price) - Heigh Pharmacias Unity	olesale Price) -	Hetel Phar	macues Only -	External invol	ľ	0	500	2
CHOIL	2,223	3 5	00.00	(a) 110m (a)	1 1 2 2	0 0 0	2000	2000	70.3%		18 CS	1 97
lithan (business only)	9717	213	609%	5 Note (1)	11.5%	ා ලද	51.5%	61.2%	70 3%		62.5%	1.97
Rural (in-state only)	2,343	36	505%	Sea Note (1)	8.8%	1 5%	52.2%	59 6%	56.9%	57.6%	83.5%	2.03
Distributions by Drug Product <sup>2</sup>	uct <sup>2</sup>		-									
Multi-Source Drug Products without an FUL and not Paid with a Direct Price (as % of the Average Wholesale Price). Extend Invoices Only	FUL and not Paid	with a Direct	Price (as % of	the Average Wh	olesale Price) -	External in	Voices Only	30 0%	AO 2%	40.7%	45.15	1 95
DE THOMAS AND THE PROPERTY OF	0.00	2 6	44.00	25.107	271%	500	15.7%	41 4%	79 494	41 8%	48 0%	1.97
Belail Pharmacies	12.050	606	43.5%	53 8%		1 28	135%	40.5%	80.3%		45.9%	1.95
Chain Retail Pharmacies	3,223	<b>4</b>	45.8%	55.8%		1.4%	14.2%	45.C%	79.8%		68.6%	1.97
Independent Relail Pharmacies	8,837	571	44.5%	54.5%	28.4%	1.2%	14,4%	41 8%	80.4%	42.3%	47.0%	1.95
1) Individual store means are weighted by Medi-Cal drug utilization, however, distributions of acquisition cost by store are not weighted	y Medi-Cal drug utili	tation, howeve	i, distributions	d acquisition cos	t by store are no	weighted						
1) individual store means are weighted of	/ Med:-Cal drug uni	zalion, noweve	i, distributions a	or acconstron cos	OF SIGHT BIR IN	nau-ban.						

2) individual drug maans are not weighted, however, the mean of the distribution of equisition cost by drug restiting from a weighted calculation is presented

CAAG/DHS0068641

Myers and Stautter CC

CA\_EAC\_exhibits.xis [MSNFND - AWP - Stats]

CA\_EAC\_exhibits.xs [MSNSHD - AWP - State]

## Multi-Source Drug Products without an FUL and Paid with a Direct Price study of Medi-Cal Pharmacy Reimbursement Pharmacy Acquisition Cost Survey Data Statistical Summary of Acquisition Costs as a Percent of the Average Wholesale Price

Delication of the second of th	700											
Stidy of Medi-Cal Fharmacy normalisement	in but settler.									95% Confidence Interval for Mean	onfidence interval for	for Mean
			General Statistics	STICES				Commen				
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	n: Number of						11. 122. 133.	E	• .		
	77	Pharmecies /	<b>3</b>	Mean (Weighted		Standard						r Yalue (with)
	Number of	Drug	<b>₹</b> 65	by Medicald	Standard E	Error of the			1			degrees
Characteristic	Observations Products		weighted) Di	(Unweighted): Drug Utilization)   Devlation   Mean	Deviation	Mean	20%	50%	80%	Bound	DOUNG O	011100000111
Distributions by Pharmacy		<u>)</u>			, , , , , , , , , , , , , , , , , , ,							
Ali Pharmacies 4.592 454 80.3% Southers (1) 4.8% 0.2% 80.0%	4,592	454	80.3%	Soo Note (1)	4.8%	0.2%	80.0%	80.9%	82.4%	79.8%	80.7%	1 97
Muti-Scurse Drug Products without an FUL and Paid with a Direct Price las % of the Average Wholesgie Price) - External invoices Only.	ז FU≿ and Paid with	a Direct Price	fas % of the A	verage Wholese	ie Price) - Ext	emai hvoko	es Only					_
Institutional and Retail	1,678	240	79.8%	See Note (1)	5.4%	0.3%	79.5%	80.5%	82.2%	79.1%	80 5%	1.97
Institutional	142	<u>.</u>	75.1%	See Note (1)	11.7%	2.9%	75.4%	78.6%	80.6%	68.8%	200	
Berail	1,536	224	801%	See Nose (5)	4.5%	0.3%	79.6%	80,5%	92.7.8	(9.3%)	00.7%	
Multi-Source Orug Products without on FUL and Paid with a Direct Price (as % of the Average Wholesale Price) - Retail Pharmacies Only - External Inveices Only	n FUE and Paid with	e Direct Price	las % of the A	verage Wholesa	le Price) - Rei	ail Pharmac	es Only - Exte	mal invoices	Only			
Chain	322	28	78.8%	See Note (1)	2.6%	0.5%	76.4%	79.5%	BO 7%	77.8%	79 8%	200
Independent	1,214	196	80.2%	See Note (1)	4.7	0.3%	80.0%	80.6%	B2 4%	79.5%	80 9%	3 4
Urban (In-state only)	1,231	191	80.2%	See Plate (1)	4 8%	(3%)	79.6%	3000	0.4	7 2 2 7 6	000	2
Rurat (In-state only)	305	<b>3</b>	79 6%	See Note (1)	30%	0.5%	79 4%	မ ပ မ	60 9%	78.5%	60 6%	20
Distributions by Drug Product <sup>2</sup>	luct <sup>2</sup>					:						
Multi-source Drug Products without in FUL and Product with a Justice Trice 18 2 Justice Average Products without in 1676 44 70,5% 56.0% 23.0% 3.5% 66	1,676	44	70.5%	76,0%	23.0%	3.6%	66.6%	8C.0%	80.3%	63.6%	77.5%	8
institutional Pharmacies	142	29	57 g%	74.6%	24.1%	4.5%	55.3%	78.5%	80.1%	56 7%	77.0%	2.05
Retail Pharmacies	1,536	43	72.5%	76.9%	20.8%	3.2%	79.5%	80.1%	8C 4%	66,3%	79.0%	2.02
Chain Retail Pharmacles	322	30	75:%	76.6%	16.2%	3.0%	79.3%	79.6%	79.6%	69.1%	91.49	2.5
Independent Retail Pharmacies	1,214	£	72.7%	77.0%	20.8%	93 80 38	79.7%	80.3%	80.6%	80.6%	19.7.61	2.5

) individual store means are weighted by Med-Cal drug unitation, however, distributions of acquisition cost by store are not weighted.

2) individual drug means are not weighted, however, the mean of the distribution of acquisition cost by drug resulting from a weighted distribution is presented.

CA\_EAC\_exhibits.xls (SSO - DP.- Stats)

Myers and Stauffer LC

CAAG/DHS0068643

# Pharmacy Acquisition Cost Survey Data Statistical Summary of Acquisition Costs as a Percent of the Direct Price Single Source Drug Products Paid with a Direct Price study of Medi-Cal Pharmacy Reimbursement

Exhibit 16

,										95% Confide	5% Confidence Interval for Mean	lor Mean
			General Statistics	files			Pe	Percentiles		bese	(based on Student f)	3
		Pharmacles /	7년 - 1년 - 발: 플러	Moon (Weighled	2	Standard			No.			Value (with
	Number of		<b>№</b>	by Medicald Standard Error of the	ndard Eri	or of the				Lower	Upper	degrees
Characteristic	Observations	Products (Un	weighted) Dr	Unweighted) Drug Utilization) Deviction		Mean	%.02	00%	9	00000	Congress	O. Hobuston
Distributions by Pharmacy	<u>.</u>											
Single Source Drug Products Paid with a Direct Price (as % of the Direct Price) - Includes Internal Involves	n a Direct Price (as	% of the Direct	Price) - Includ	es internal invoices	•							
All Pharmecies	32,498	480	95.4%	See Note (1)	21%	0.1%	93 8%	95 5%	%0 / E	82.2%	95 6%	 a
Single Source Drug Products Paid with a Direct Price (as % of the Direct Price) - External involces Only	h e Direct Price (as	% of the Direct	Price) - Extern	sal invoices Only								
Institutional and Retail	9,694	265	94.5%	See Note (1)	2.3%	0.1%	92.8%	94 4%	95.9%	94.2%	94.6%	. 9
Institutional	623	18	%3 66	San Note (1)	3 2%	0.7%	90.8%	9,678	S. C.	52.0.26	90.73	
Retail	9,071	247	94.6%	See Note (1)	, ye	0.1%	93.1%	94 5%	82 9%	94,3%	34 375	7.8.
Single Source Drug Products Paid with a Direct Price (as % of the Direct Price) - Retail Pharmacies Only - External Involces Only	h a Direct Price (as	% of the Direct	Price) - Retali	Pharmacies Only -	External lave	Aluo saoid	•					
Chain	2,406	28	94:%	See Note (1)	1 1%	0.2%	93.5%	94.0%	94.7%	33.7%	94.6%	2.05
Independent	6,555	219	94.6%	Sae Note (1)	2.3%	0.2%	930%	94.6%	96.1%	34,3%	95.0%	
Urben (In-state only)	6,954	210	94.7%	See Note (1)	2.3%	0.2%	93.1%	94.7%	98.1%	94,4%	95.0%	1 97
Rural (In-state only)	2,117	37	93.8%	See Note (1)	19%	0.3%	92.6%	93.9%	94 76	93.1%	94 4%	2,03
Distributions by Drug Product <sup>2</sup>	luct <sup>2</sup>											
Single Source Drug Products Paid with a Difect Price tas % of the Direct Price; - External Products Only	a Difect Price (as	% of the Urect	Price: - EXtern	ial involces only	3	}		3	3	200	9	9
All the macies	9,694	2 2	9/4%	90.9%		2 6	930%	00 4 4	8 8	0000	00.00	4 .
Institutional Pharmacras			0 0 0	94 076	2 6				3	707	0 1	100
Helail Phormacies	9,07	ē	2/.3/6	90.0%	4	0.476	90.00	20.0%	5	200	100	
Chain Retail Pharmacies	2,406	126	96.5%	95.3%	4 7%	0.4%	94.3%	99.2%	99.0%	95.7%	97.4%	1.95
Independent Retail Pharmacies	8,665	149	97.7%	96.2%	4.8%	0.4%	95,4%	100.2%	100 g 60	96.9%	98.0%	

1) Individual store means are neighted by Medi-Cal drug utilization, however, distributions of acquisition cost by store are not weighted calculation is presented.
2) Individual drug means are not weighted, however, the mean of the distribution of acquisition cost by drug resulting from a weighted calculation is presented.

# Pharmacy Acquisition Cost Survey Data Statistical Summary of Acquisition Costs as a Percent of the Direct Price Multi-Source Drug Products without an FUL and Paid with a Direct Price study of Medi-Caf Pharmacy Reimbursement

			Ganaral Statistics					Percentiles		95% Confid	onfidence interval for (based on Student f)	95% Confidence interval for Mean. (based on Student f)
			Colored Day									
		Pharmacies /		Mean (Weighted		Slandard						* Yalue (with
	Number of	Drug	K 227	by Medicald	Slandard E	Error of the				Lower	Upper	n-1 degrees
Characteriatio	Observations	11.7	(Unwelghted)	Drug Utilization) Deviation	Deviation	Mean	20%	50%	80%	Bound	Bound	of freedom)
Distributions by Pharmacy	~, -											
Multi-Source Drug Products without an FUL and Paid with a Direct Price (as % of the Direct Price) - Includes Internal Invoices	n FUL and Paid wil	h a Direct Pri	ed (as % of the	Direct Price) - In	cludes Internal	Invoices					<u> </u>	I
All Pharmacies	4,592	\$	95.5%	See Note (1)	6.7%	0.3%	91 9%	96 7%	%001	94 9%	96.1%	1 97
MuniSource Drug Products without an EUL and Paid with a Direct Price (as % of the Direct Price) - External Invoices Only	n FUL and Paid wit	h e Direct Pri	ce (as % of the	Direct Price) - Ex	rtemai invoices	YIIIO						
Institutional and Refail	1.678	240	93.7%	See Note (1)	7.0%	0.5%	90.5%	95.56	3B 3%	92.6%	94.6%	1 97
Institutional	142	16	90.7%	See Note (1)	13.5%	3.4%	88 3%	83.6%	96.7%		9,457.6	2.16
Retail	1,536	224	94.0%	See Hote (1)	6.3%	0.4%	90.5%	952%	%E B\$	931%	94.8%	1 97
MUPLSource Drug Products without an FUL and Paid with a Direct Price (as % of the Direct Price) - Relail Pharmacies Only - Exismal Invoices Only	n FUL and Paid wit	h a Direct Pri	ce (as % of the	Direct Price) - Re	elail Pharmacic	s Only - Ex	ernal Invoice	\$ Only				
Chain	322	28	92.4%	See Note (1)	3,9%	0.7%	88.1%	92.5%	95.6%	90.9%	93.9%	2.06
Independent	1.214	196	94 2%	Soe Note (1)	0.6%	0.5%	906%	95.5%	98 86		95.1%	1.97
Urban (In-state only)	1.231	191	93.8%	See Note (1)	5.5%	0.5%	90 4%	%0.95	35E BE		84 8%	1 97
Rural (in-state only)	305	ដ	94.6%	Sep Note (1)	499	0.9%	908%	98 0%	98 2%	92.8%	96.3%	<u>م</u>
Distributions by Drug Product <sup>2</sup>	duct <sup>2</sup>											
Multi-Source Orug Products without an FUL and Pald with a Direct Price less % of the Direct Price; external invoices Only.  All Pharmacies 90.4% 28.5% 4	n FUL and Pald wit	h a Direct Pris	ce (as % of the	Oirect Price) - Ex	kternal Invoices	4 3%	67 5%	95 0%	100.0%		91 4%	
Institutional Pharmacies	142	230	79.0%	88 7%		56%	547%	92.1%	%0.001		90 4%	
Retail Pharmacies	1,536	43	95.2%	91.4%		4.0%	%8 OB	3×3%	100.0%		93 2%	
Chain Retail Pharmacies	322	30	87.8%	93.4%		4.0%	87.3%	945%	99 4%	79.7%	96.0%	2.05
independent Retall Pharmacies	1,214	43	85.3%	91.6%		4.0%	808%	\$5 5°	 8	77.2%	93 3%	
1) Individual store means are weighted by Medi-Cal drug utilization, however, distributions of acquisition cost by store are not weighted	by Madi-Cal drug util	Zation, howeve	er, distributions	of acquisition cost	by sione are no.	weighted						
1 00 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	A ANDREO OF CHARLES	ACCIDITATION OF THE PARTY OF TH	or Control Control	A CONTRACTOR OF THE PARTY OF TH	Cracio orderio	2000						

Individual drug means are not weighted, however, the mean of the distribution of acquisition cost by drug resulting from a weighted calculation is presented.